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ABSTRACT 
Introduction: Individuals with type 1 diabetes require lifelong insulin supply as well as 
behavioral adjustments for good treatment result. Only a minority reach the goal for glycemic 
control set in order to reduce the risk of severe long-term complications. Interventions based on 
cognitive behavior therapy (CBT) have been proposed to improve diabetes-management, but 
evidence for its efficacy in adults with poorly controlled type 1 diabetes is sparse. One common 
barrier to optimal diabetes-management is fear of hypoglycemia (FOH), especially in those who 
have experienced severe hypoglycemic episodes. Thus there is a need for a valid and reliable 
instrument to assess individuals who are affected by FOH. It is also vital to identify factors 
associated with FOH in order to find targets for interventions to reduce fear. 
Aim: The overall aims of this thesis were to evaluate a CBT intervention for poorly controlled 
individuals with type 1 diabetes and to explore fear of hypoglycemia in an effort to gain deeper 
knowledge of possible targets for interventions to reduce FOH. 
Methods: All four studies applied quantitative designs. Study I was a randomized controlled 
trial in which a cognitive behavioral intervention was evaluated on poorly controlled adult 
persons with type 1 diabetes. Study II was a psychometric evaluation of a Swedish version of 
the Hypoglycemia Fear Survey (HFS) in a survey study in adult persons with type 1 diabetes. 
Studies III and IV were cross-sectional survey studies employed on adults with type 1 diabetes 
exploring disease-specific, demographic, (studies III and IV) emotional and psychosocial 
factors (study IV) related to FOH. 
Results and conclusions: Study I: The intervention group receiving CBT showed significant 
improvements in HbA1c, diabetes related distress, well-being, FOH, perceived stress, anxiety 
and depression as well as frequency in self monitoring of blood glucose. Study II: A three-
factor solution was found for the Swedish version of the HFS with the dimensions Worry, 
Behavior and Aloneness. Cronbach’s alpha for the total scale was 0.85 and varied between 0.63 
– 0.89 in the subscales. Convergent validity was also supported with moderate correlation 
between Swe-HFS and Swe-PAID-20. The Swe-HFS seems to be a reliable and valid 
instrument to measure FOH in adults with type 1 diabetes. Study III: Seven hundred and sixty-
four persons (55%) responded to the questionnaire. The HFS-Worry subscale was significantly 
associated with frequency of severe hypoglycemia, number of symptoms during mild 
hypoglycemia, gender, hypoglycemic symptoms during hyperglycemia and hypoglycemic 
unawareness. The HFS-Aloneness subscale was significantly associated with frequency of 
severe hypoglycemia, number of symptoms during mild hypoglycemia, gender, frequency of 
mild hypoglycemia, HbA1c, hypoglycaemic unawareness and visits to the emergency room 
because of severe hypoglycemia. FOH proved to be more prevalent in females. Frequency of 
severe hypoglycemia was identified as the most important factor associated with FOH.  Study 
IV: A total of 469 (61%) persons responded to the questionnaire. The HFS was significantly 
associated with The Anxiety Sensitivity Index, the Anxiety subscale of Hospital Anxiety and 
Depression Scale and Social Phobia Scale. Together with the disease-specific factors the 
regression model explained 39% of the variance. Support for a positive association between 
FOH and anxiety was present and previously identified gender differences were confirmed. 
Differences between the subgroups on factors associated with FOH were found that may have 
implications in developing interventions. 
 
Key words: type 1 diabetes, fear of hypoglycemia, psychometrics, behavior modification, 
cognitive behavior therapy, behavioral medicine, glycemic control. 
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1 INTRODUCTION 
Type 1 diabetes is considered one of the most challenging chronic diseases (1), 
requiring lifelong insulin supply as well as behavioral adjustments in order to survive. 
Since the development of insulin in the 1920’s, advancements in medical treatment 
have led to remarkable improvements in the survival rate, reductions in the rate of 
complications and a better quality of life (QoL) for people with diabetes. Multiple 
injection therapy and the possibility to self-monitor blood glucose are two factors 
making life easier to maneuver according to individual wishes. On the other hand, 
statistics from the Swedish National Diabetes Registry (NDR) (2) show that only a 
minority of individuals reach the goal for glycemic control set by the National Board of 
Health and Welfare (3). Even though recommended therapy with intensive insulin 
treatment has led to improvements in many areas it is also highly demanding and 
difficult, requiring the individuals to make daily decisions that affect their blood 
glucose level. Thus, they have to balance the threat of acute complications such as 
hypoglycemia i.e. low blood glucose with the risk of hyperglycemia (high blood 
glucose) which in the long run results in increased risk of long-term complications.  
 
The thorough behavior changes required in maintaining good self-care may be 
burdensome (4) and diabetes does not only affect the person physically but has also 
been shown to be associated with higher prevalence of depression and anxiety (5-6).  
Poor psychological health, in turn, has been associated with poor glycemic control (7). 
One common barrier to optimal diabetes-management is fear of hypoglycemia, a 
problem strongly associated with having the experience of severe hypoglycemia, i.e. 
the inability to self-treat hypoglycemia. Because the risk of SH has increased three-fold 
with the intensive insulin treatment regimen (8), the problem of FOH now may affect a 
larger proportion of individuals.  
 
For many individuals with type 1 diabetes, poor glycemic control is thus likely 
associated with problems adhering to the treatment regimen. There is also data 
indicating that poor glycemic control is unlikely to improve without specific 
interventions aimed at improving control (9).  Despite all of the above in mind, 
surprisingly little research has been done in developing and evaluating methods 
facilitating the necessary behavior changes and the psychological challenges associated 
with diabetes. Cognitive behavior therapy (CBT), a psychotherapy anchored in research 
and the principles of learning theory, has been shown to be effective in several somatic 
problems, including cardiovascular disease (10) and pain (11) in aiding people in 
necessary behavior change as well as handling emotional challenges associated with 
chronic disease. This suggests that a CBT intervention with the aim of improving 
glycemic control by targeting problems adhering to the treatment regimen may be 
helpful.  
 
This thesis has three aims: evaluate the effect of a CBT-intervention on diabetes 
management, assess an instrument measuring FOH, and explore factors associated with 
FOH with the intent to find important targets for interventions to reduce FOH.  
 2 
2 BACKGROUND 
 
2.1 THEORETICAL FRAMEWORK 
The overarching theoretical framework of this thesis is the biopsychosocial model (12) 
included in a behavioral medicine perspective. CBT is a form of therapy based on 
theories in concordance with the biopsychosocial model and is an important basis of the 
theoretical framework of this thesis. 
 
2.1.1 Behavioral medicine and the biopsychosocial model 
Traditionally, within medicine, a reductionistic, biomedical model in which disease is 
viewed as being caused by biological deficiency or damage has been adopted. In the 
1970´-s Engel presented an alternative view, namely the biopsychosocial model. This 
model expands the view of disease including the importance of many more concepts 
such as the behavior of the patient, the social and cultural context in which they live, as 
well as the medical environment along with the biological perspective in order to 
understand the disease and to devise treatment. Engel shows the importance of these 
concepts with diabetes. He emphasizes the importance of the relationship between the 
medical caretaker and the patient in the outcome of treatment.  
 
Engel also touches on the definitions of the concepts on health and disease:  ”The 
boundaries between health and disease, between sick and well, are far from clear and 
will never be clear, for they are diffused by cultural, social, and psychological 
considerations” (12). 
 
Thus it is assumed that behavior and lifestyle factors (defined as habits or automated, 
frequent behavior performed on a daily basis) can play a role in the occurrence, 
development and treatment outcome of the disease. This view assumes that it also holds 
true for type 1 diabetes in which the treatment outcome to a large extent depends on the 
individual being able to self-manage the disease.  
 
The field of behavioral medicine adopts the biopsychosocial model. An early definition 
of behavioral medicine was given by Schwartz and Weiss shortly after Engel presented 
his model: 
 
“Behavioral medicine is the interdisciplinary field concerned with the development and 
integration of behavioral and biomedical science knowledge and techniques relevant to 
health and illness and the application of this knowledge and these techniques to 
prevention, diagnosis, treatment and rehabilitation”(13). 
 
A more narrow, and perhaps, more controversial definition reflecting a dominance of 
behavior therapy in the field, is Pinkerton et al.’s, 1982 definition (14): 
 
”The clinical application of principles, techniques, and procedures of behavior therapy 
in the assessment, treatment, management, rehabilitation and prevention of physical 
disease or concomitant behavioral reactions to physical dysfunction…” 
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What these definitions have in common is that behavior medicine is a wide field 
encompassing the whole chain of necessary actions to promote health, from prevention 
to assessment and treatment. This thesis falls within the field of behavioral medicine, 
adopting the biopsychosocial model in studying type 1 diabetes and how to overcome 
barriers of glycemic control. It takes into account biological, behavioral and social 
factors and uses principals and methods from CBT as well as the medical field. 
 
2.1.2 Cognitive behavior therapy  
Interventions based on CBT have been widely researched and used in the field of 
behavioral medicine. Further, these interventions have proven effective in a number of 
distinct somatic problems such as cardiovascular disease (10), cancer (15), tinnitus 
(16), irritable bowel syndrom (17-18), pain (19), sleep disorders (20) and epilepsy (21). 
 
CBT is a psychotherapy anchored in research in the fields of learning theory, social 
psychology and cognitive theory encompassing numerous evidence-based methods. 
The intervention used in study I is mainly based on learning theory including the 
principles of operant and respondent learning. Fundamental to learning theory is the 
assumption that behavior is learned through a complex interaction between the 
individual and her context, making behavior change possible through new learning 
experiences. According to behaviorism, behavior is defined as both external, visible 
actions and internal responses such as thoughts, emotions and physiological reactions. 
A distinction is made between voluntary and respondent behavior. Operant learning 
refers to behavior modified by its consequences, and respondent learning or classical 
conditioning to behavior elicited by antecedents.  
 
The principals of operant and respondent learning are the foundations of functional 
behavior analysis, a method of making sense of most human behavior, even highly 
dysfunctional or harmful behavior. How does this relate to diabetes? Well, diabetes 
changes the individual’s internal and external environment. Internal responses and 
reflexes are altered as a result of insulin deficiency, producing physical symptoms that 
may be highly unpleasant and at times hard to interpret. These internal changes require 
external adaptation through behavior change in order to successfully treat the disease. 
The behavior change needed is often not directly reinforced but may instead be 
aversive to the individual. For example, testing blood glucose (BG), a behavior 
recommended to successfully adjust the BG level, may directly be painful and thus 
aversive to the individual, especially if the person does not know how to interpret the 
BG or does not believe she can control the BG by making adjustments. Because CBT 
has proven effective in achieving behavior change in a number of chronic diseases it 
may well be beneficial for persons with type 1 diabetes (16, 22-23). 
 
2.2 DIABETES MELLITUS 
Diabetes mellitus (hereafter referred to as diabetes) is not one disease but a term used to 
describe several different diseases characterized by hyperglycemia or high BG levels. 
The two main types of diabetes are called type 1 and type 2 and differ in etiology.  The 
International Diabetes Federation (IDF) reported that in 2011 there were approximately 
366 million people with diabetes (24) and it is estimated that the global prevalence in 
2030 will have increased to 552 million individuals, i.e. an increase from 8.3% to or 
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9.9% of the adult population. According to the same report, in 2011, 4.6 million people 
died from diabetes, with nearly 50% being younger than 60 years (24). 
 
In the annual report 2011 from NDR (2) there were about 350 000 individuals with 
diabetes in Sweden giving a prevalence of 3.5%. Of those approximately 10% were 
diagnosed with type 1 diabetes and the remaining 90% with type 2 diabetes.   
 
In 2006, the healthcare cost for diabetes in Sweden was estimated to 8% of the total 
healthcare cost (25). This high figure is mainly due to long-term kidney, eye, nerve and 
cardio-vascular complications of diabetes. 
 
2.2.1  Type 1 diabetes 
This thesis concerns type 1 diabetes.  In type 1 diabetes the beta cells involved in 
producing insulin in the pancreas are damaged, most often by an autoimmune 
inflammation, resulting in absolute insulin deficiency. This means that the individual 
affected must inject insulin every day to survive. Type 1 diabetes usually has an onset 
in childhood with the highest incidence rate between the age of 5 and 14 years but can 
affect all age groups. In the majority of patients auto-antibodies can be detected in the 
blood (26). 
 
2.2.2 Complications  
Although the possibilities of treating diabetes effectively have improved immensely 
over the past decades, having diabetes increases the risk of a multitude of long-term 
complications of which many have serious implications to the individual’s life. Perhaps 
most alarming is that people with type 1 diabetes still have a shorter life expectancy 
than healthy individuals. Complications resulting from diabetes are often categorized as 
either acute-, or long-term complications (26). 
 
2.2.2.1 Acute complications 
Acute complications include hypoglycemia (low BG level) and ketoacidosis both of 
which can be fatal. Hypoglycemia is described in more detail in a separate section. 
Ketoacidosis, a serious and life-threatening condition that requires immediate treatment 
is characterized by hyperglycemia, loss of fluid and formation of ketone bodies that 
make the blood acidic. Insulin deficiency often due to omission of insulin is a common 
cause of this complication. Mortality due to ketoacidosis has decreased but still occurs 
in type 1 diabetes (26).  
 
2.2.2.2 Long-term complications 
There is an increased risk of developing a number of medical complications as a result 
of having diabetes. Chronically raised glucose levels associated with the disease leads 
to damage of the small blood vessels in many organs including the eyes (retinopathy), 
nerves (neuropathy) and kidneys (nephropathy) (8, 27). Retinopathy, is the most 
common cause of acquired blindness in adults in industrialized countries. However, 
diagnosed at an early stage this complication can often be treated successfully.  
Neuropathy, most often leads to sensory loss of the lower extremities which contributes 
to the occurrence of foot ulcers but can also affect a number of important functions 
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such as digestion, blood pressure and sexual ability. Nephropathy, may result in renal 
failure and the need for dialysis treatment or transplantation (26). Cardiovascular 
complications also occur because of macrovascular disease, i.e. changes in the larger 
arteries. Such changes increase the risk for myocardial infarction, congestive heart 
failure, stroke and gangrene of the feet. The increased risk of cardiovascular 
complications in people with diabetes is linked to the increased prevalence of other risk 
factors (e.g., elevated cholesterol and blood pressure and tobacco use) (26).  
 
 
2.2.3 Treatment and treatment goals 
Guidelines from the National Board of Health and Welfare (3) state that the 
overarching treatment goal for diabetes is to prevent acute and long-term 
complications, while maintaining high QoL for the patient. For type 1 diabetes the 
recommendation is to to strive for the best possible glycemic control through intensive 
insulin treatment. Furthermore all persons should be given the possibility of systematic 
self-monitoring of blood glucose without cost and have access to regular screening for 
retinal disease as well as for other complications. Health and medical care should also 
invest in effective treatments to reduce blood pressure and cholesterol in addition to 
helping people with diabetes to increase their physical activity and to stop smoking. 
Finally, the guidelines state that group-based patient training that is led by persons with 
both specialist competence and pedagogical competence should be given especially to 
patients who have unsatisfactory glucose control. 
 
In Sweden a person with type 1 diabetes normally receives treatment from an 
“outpatient” diabetes care unit in a hospital, in which a physician often is seen once or 
twice a year and a diabetes specialist nurse twice to four times a year. Other professions 
included in the diabetes care team are usually a dietician, a podiatrist, a social worker 
and a physical therapist (3). Psychologists are more seldom part of the team. Usually 
some form of patient education is offered to the individual, often in group format. The 
actual treatment is mainly performed by the person with diabetes on a daily basis and 
requires a number of self-care behavior described below.  
 
2.2.3.1 Glycemic control and HbA1c 
Glycemic control is mainly measured with HbA1c, or glycated hemoglobin which 
reflects the average BG level in the past 8-12 weeks. Several methods to measure 
HbA1c are available and until recently there was no global consensus on which standard 
to use, making it difficult to compare results from different nations.  In October 2010 
agreement was reached to use mmol/mol as the standard set by the International 
Federation of Clinical Chemistry and laboratory (IFCC). In the present four studies, 
performed before October 2010, HbA1c is measured and reported using the Swedish 
Mono-S method with reference value 3.6-5.2%. The Mono-S method is 0.9-1,0 % 
lower than the standard set by the Diabetes Control and Complications Trial (DCCT) in 
the US. In Sweden, the target value for satisfactory glycemic control is set at HbA1c < 
52 mmol/mol or < 6.0% (MonoS). 
 
In 2011 only 15% of individuals with type 1 diabetes in Sweden reached the glycemic 
goal according to the NDR (2). The average HbA1c was 65mmol/l and as many as 23% 
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had HbA1c ≥ 73 mmol/mol. These figures indicate that it is difficult to achieve the 
glycemic goal for a large majority of individuals with type 1 diabetes. 
 
2.2.4 Self-care behavior 
It is a challenging task to balance self-care behavior to avoid short-term complications, 
such as hypoglycemia with the need for near normal BG in order to minimize the risk 
of long-term complications. Diabetes management requires life-long attention to insulin 
injections, BG tests and quite complex calculations of the effect various behaviors have 
on the BG level. The thorough behavior changes required in maintaining good self-care 
may be burdensome (4). A person with type 1 diabetes needs to take multiple daily 
injections of insulin and to make decisions on how large a dose is needed at that 
moment. The insulin requirement depends on the present BG level, if and what the 
person is about to eat, degree of past and of planned physical activity, level of stress, 
whether the person has an infection, and whether the person has or is about to consume 
alcohol. Even when adhering fully to recommendations given by medical experts 
neither control over BG, nor avoidance of complications is guaranteed. 
 
In addition to insulin injections, self monitoring of blood glucose (SMBG) and the daily 
decisions on how to balance food and activities to reach the best glucose level possible 
there are recommendations on becoming non-smoking and having regular foot 
inspections (26).  
 
With this in mind it is not hard to appreciate why many people with diabetes feel 
overwhelmed with the treatment and may “give up” trying to reach glycemic control. 
The fact that “non-adherence” and poor glycemic control may not in the short run have 
any impact on the physical health, may also be of significant importance in the majority 
of individuals with type 1 diabetes not reaching the target value for glycemic control.  
 
2.3 BARRIERS OF SATISFACTORY GLYCEMIC CONTROL  
Difficulty in adhering to the complex and demanding self-care described above seems 
intuitively to be a major reason why only 15% of all adults in Sweden with type 1 
diabetes reach the goal for glycemic control, but what does research tell us about the 
barriers to good glycemic control? Studies show that this is a heterogeneous, individual 
problem. Common barriers, discussed in a review by Devries et al.., (28) range from 
genetic variation to demographic and psychosocial factors. A demographic factor with 
multiple support for an association with poor glycemic control is lower socioeconomic 
status. Less diabetes knowledge and less frequent SMBG are other factors explaining 
poor control (29-30). Psychological comorbidity is associated with poorer glycemic 
control and may be a significant factor contributing to the problem in many individuals 
in that there is an increased prevalence of several psychiatric disorders in this 
population (7). For instance depression is 2-4 times more prevalent in persons with 
diabetes (31) and is associated with poor glycemic control, higher mortality and 
morbidity as well as decreased QoL (5) . There are also data to support a link between 
anxiety, eating disorder and glycemic control (6, 32).  Diabetes related distress which is 
a concern about diabetes management, emotional burden and support, has also been 
found to be a barrier (33). Furthermore a link between stress and poor glycemic control 
has been found in several studies (34-36). Stress may affect glycemic control as a direct 
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result of the physiological mechanisms involved. Evidence exists that stress can have 
stimulatory effects on insulin antagonists such as cortisol, adrenaline, glucagon and 
growth hormone (37) leading to impairment of insulin sensitivity that has been found to 
persist for at least 6 hours after the maximal stress (38). The mechanism may also be 
indirect because the psychological effect of stress may impact mood and self-care 
behavior in a negative way. Psychological problems specifically linked to diabetes such 
as fear of complications and fear of hypoglycemia have recently received attention as 
major barriers (39-41). Many of the above mentioned barriers include problems 
adhering to the treatment regimen and thus reflect behavioral barriers. This thesis 
focuses on behavioral barriers of glycemic control including FOH, which is discussed 
later in the thesis. 
 
2.3.1 Behavioral barriers in self-care: fear and avoidance 
In many cases difficulties with self-care can be explained from a behavior analytic 
perspective as avoidance behavior. The definition of avoidance behavior is that it is 
behavior negatively reinforced, i.e. it is behavior done in order to avoid something 
regarded as unpleasant or unwanted. Many of the self-care behavior needed may have 
immediate negative effect on the person: for instance SMBG may be painful, lead to 
negative mood if an unwanted blood glucose level is registered, involve hassle in 
planning and bringing the BG-meter or be embarrassing to show others, and may, for 
any of these reasons be avoided. The purpose of SMBG is to enable the person to 
actively manage his or her glucose level by adjusting insulin, food or exercise. For 
those who experience successful adaptation to a registered BG the behavior of SMBG 
is probably positively reinforced, which means that they he or she is likely to use 
SMBG in a similar situation again. However, this is a more long-term effect and 
because behavior is more easily learnt from immediate consequences, the behavior of 
SMBG may not be reinforced. The same principles apply to other behavior such as 
exercise that has more long-term benefits for glycemic control and health, but may in 
the short run lead to aversive experiences of becoming tired and of episodes of 
hypoglycemia. Adjusting the kind and amount of food eaten in order to balance BG and 
maintaining a healthy weight may not only be difficult because it involves immediate 
aversive consequences (e.g., planning ahead and negative mood thinking about the 
disease), but also because the alternative may be immediately reinforcing while 
negative consequences appear in the future, (e.g. eating the chocolate is immediately 
reinforced if it tastes good, but the weight gain or an increase in BG is not detected 
until later).  
 
Fear and anxiety are central in some of the avoidance behavior related to self-care in 
diabetes, for example fear of hypoglycemia. Fear is an innate response to a threat, i.e. a 
response that does not need to be learned. The purpose of the response is to prepare the 
person for fight or flight in order to increase chances of survival. With fear comes an 
impulse to escape and avoid, appropriate responses increasing the chance of survival 
when a threat actually exists. Fear is easily conditioned so that the fear response can be 
elicited in the presence of non-dangerous stimuli associated with the actual threat, for 
instance, fear as a response to the thought of hypoglycemia or the sight of a place 
where one has experienced hypoglycemia. A distinction sometimes made between fear 
and anxiety is that fear is a response to a dangerous stimulus being present, whereas 
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anxiety is a fear response without the presence of a dangerous stimulus. Marks (42) 
uses the term phobic fear when “fear is out of proportion to the demands of the 
situation; it cannot be explained or reasoned away; it is not under voluntary control; 
and the fear leads to avoidance of the situation”. A problem with anxiety or phobic 
fear as defined above is that when the fear response is elicited, escape is the primary 
focus of our attention instead of evaluation of the real danger. Once frightened, we tend 
to avoid not only the specific fear stimulus but also conditioned stimuli. This avoidance 
of non-dangerous stimuli prevents the individual from experiencing and thus learning 
that the stimuli are not dangerous, creating a vicious circle in which anxiety may spread 
to other situations which limits the individual from taking part in certain activities. A 
model that explains this process of fear acquisition and maintenance is the two-factor 
model developed by Mowrer over 60 years ago (43). The name of the model stems 
from the fact that it includes both respondent and operant learning. Assumed in this 
thesis is the notion that fear and avoidance as described by the two-factor model may 
be useful in explaining the acquisition and maintenance of FOH.  
 
 
2.3.2 Hypoglycemia  
Hypoglycemia is considered the most important limiting factor in reaching normal 
glucose levels in individuals with diabetes (44). It is the most common adverse event in 
type 1 diabetes and if left untreated, it can become dangerous and even life-threatening. 
In healthy individuals hypoglycemia is mainly prevented or reversed by an autonomic 
decrease of insulin production. For individuals with type 1 diabetes this is not possible 
since the insulin that has been injected cannot be rapidly decreased. Instead an active 
treatment by intake of foods high in carbohydrates such as sugar, fruit, milk or candy is 
required. Low BG also normally activates a counter regulatory system of stress 
hormones in order to stop the glucose level from falling, creating symptoms by most 
people experienced as unpleasant, such as rapid heartbeat, increased sweating, shaking, 
hunger and difficulty concentrating. One of the purposes of these symptoms is to serve 
as a warning signal and to activate an impulse to eat something in order to raise the 
glucose level. In some individuals with diabetes hormonal counter regulation become 
impaired. Attenuated sympathoadrenal responses to hypoglycemia lead to reduced 
symptoms during hypoglycemia and causes the clinical syndrome of impaired 
awareness of hypoglycemia or hypoglycemia unawareness which increases the risk of 
severe hypoglycemia (45-46). This syndrome is most often caused by recurrent 
antecedent hypoglycemic episodes and is often reversible by careful avoidance of low 
BG-values (47).  
 
Below a more detailed description is given of what constitutes a hypoglycemic episode, 
of the associated symptoms, causes, the prevalence and the physical, psychological and 
economic impact hypoglycemia has on the individual. 
 
2.3.2.1 Definitions of hypoglycemia 
There is no consensus on a definition of hypoglycemia in diabetes. Classically, three 
criteria had to be documented (in Frier and Fisher, 2007 (47) referred to as Whipple’s 
triad from year 1938): 1) symptoms and or signs of hypoglycemia, 2) a reliably 
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measured low plasma glucose concentration and 3) resolution of those symptoms and 
signs after plasma glucose is raised.  
 
What exactly then is a (too) low plasma glucose concentration? According to the 
American Diabetes Association (ADA) a blood glucose concentration of ≤ 3.9 mmol/l 
constitutes a hypoglycemia (48). The reason for choosing this level is that in healthy 
individuals the reduction of endogenous insulin production and the onset of the 
hormonal counter regulation occur at or below this glucose level. On the other hand, 
The European Agency for Evaluation of Medical Products (EMEA) has suggested a 
level of < 3.0 as hypoglycemic (49). At this glucose level cognitive dysfunction occurs 
and the avoidance of glucose levels < 3.0 mmol/l has been shown to restore symptoms 
in individuals with unawareness of hypoglycemia.  
 
In healthy individuals symptoms of hypoglycemia start at a plasma glucose level 
around 3.0 mmol/l (44). In individuals with elevated levels of BG symptoms of 
hypoglycemia can occur if BG rapidly falls but still remain elevated.  
 
There are several terms in the literature relating to hypoglycemia, of clinical value (47):   
 
• Asymptomatic hypoglycemia: this is a low BG detected by routine test without 
the person having any symptoms or signs of hypoglycemia. Having frequent 
asymptomatic hypoglycemia is suggestive of impaired hypoglycemic awareness 
(45-46). 
• Mild symptomatic hypoglycemia: the person experience symptoms suggestive 
of hypoglycemia and is successful in treating the symptoms, without assistance. 
A blood glucose test showing low BG makes the definition more robust. 
• Severe hypoglycemia: an episode in which assistance from a third party is 
required to reverse the hypoglycemia. The person may be unconscious but can 
be conscious though likely suffering cognitive dysfunction making it impossible 
to effectuate the treatment. 
2.3.2.2 Causes 
Hypoglycemia is caused by an imbalance between the amount of insulin in the blood 
and the amount of glucose ingested from carbohydrates and from the liver. The 
imbalance can occur in several ways: by missing a meal, by injecting an excessive 
insulin dose, or if the insulin sensitivity is increased, for example after exercise (47). 
 
2.3.2.3 Symptoms and symptom recognition 
Symptoms of hypoglycemia are highly individual and may vary from time to time (47). 
The earliest symptoms detected are normally autonomic and include sweating, 
palpitations, shaking, hunger, warmness, tiredness and difficulty concentrating (50). If 
not treated at this stage neuroglycopenic symptoms occur, including cognitive 
dysfunction such as confusion, odd behavior, speech difficulty, lack of coordination and 
blurred vision, but also anxiety, drowsiness, weakness, seizures and unconsciousness 
(51). Other common symptoms are headache and nausea (52). Hypoglycemia also 
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affects mood with most people feeling less happy, less energetic and more tension (53-
55). In addition some people report feelings of increased anger and irritation (56-57).   
 
Many of the hypoglycemia symptoms overlap with symptoms of anxiety which may 
complicate interpreting symptoms correctly. Such a misinterpretation may lead either to 
missing an otherwise easily treated mild hypoglycemic episode, thus risking a more 
severe episode, or to treating anxiety as hypoglycemia, resulting in an unnecessary 
increase in the BG level (58). According to a study by Cox et al.. (59) the most useful 
symptoms in detecting hypoglycemia are sweating, trembling, difficulty concentrating, 
nervousness, tenseness, light-headedness and dizziness. In an older study by 
Pennebaker (60) the symptoms most correctly associated with the actual BG level 
were: hunger (correctly associated by 53% of the individuals), trembling (33%), 
weakness (27%), light-headedness (20%) and pounding heart, (17%). 
 
2.3.2.4 Frequency  
It is difficult to accurately estimate the frequency of hypoglycemia mainly because 
most episodes occur without medical staff present to verify the hypoglycemia but also 
due to the different definitions used. Retrospective studies may therefore be biased. 
One must also take into account that factors such as age, duration of diabetes and 
present glucose control have an impact on frequency of hypoglycemia. Retrospective 
studies in which patients are asked to recall mild symptomatic hypoglycemia in the past 
week show an average of two episodes per week (61-62). Prospective studies have 
found somewhat fewer episodes (0.8- 1.7 episodes /week) (63-64).  The range has been 
wide in some studies. For instance in Janssen et al. (65) the episodes ranged from 0 to 
41 episodes over a six-week period. Retrospective recall of SH is somewhat more 
reliable since the consequences are more profound and manifestible. Frequency of SH 
averages between 1 and 1.6 episodes per patient/year (61-62, 64, 66-68). What may be 
more interesting than the average frequency is proportion affected. In the above studies 
the proportion ranged from 34 to 41 %. Estimates are that a majority of patients do not 
experience a SH every year but instead a smaller part of the population experience 
several episodes of SH. 
 
2.3.2.5 Impact 
As discussed above, untreated hypoglycemia can lead to coma and death. Coma is due 
to the brain suffering fuel deprivation, which may result in functional brain failure. This 
condition is in most cases reversible when the glucose level is raised but prolonged 
profound hypoglycemia may result in brain death (69). In two recent studies (70-71) 
mortality due to suspected hypoglycemia ranged between 6-10% of total mortality in 
the population of type 1 diabetes. The mortality may be due to brain death or cardiac 
arrhythmias (69) but because it is difficult to prove hypoglycemia being cause of death 
mortality rates are uncertain.  
 
In young to middle-aged adults with type 1 diabetes repeated hypoglycemia does not 
seem to be associated with cognitive impairment (66). There is, however, concern that 
repeated, frequent hypoglycemia may result in permanent cognitive impairment in 
young children, although a longitudinal study in which over 1000 patients with diabetes 
were followed over 18 years did not find an association between hypoglycemia and 
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impaired cognitive functioning (66). In support of the concern that frequent 
hypoglycemia affects cognitive functioning, two studies show specific cognitive 
impairment in children < 5 years of age that were repeatedly exposed to SH. The first 
study found an association with impaired spatial long-term memory performance (72) 
and the second study found an association with smaller left superior temporal gray 
matter volume (73).  For adults, there is not enough evidence on how repeated 
hypoglycemia affects cognitive functioning. 
 
In addition, hypoglycemia may have other severe consequences such as automobile 
accidents (74-75) or other injuries as well as causing social embarrassment and 
dismissal.  
 
Hypoglycemia also impacts self-management and productivity. In a study by Brod et 
al. (76) 25% decreased their insulin level after a non-severe episode. In a study by 
Leiter et al. (77) reported that between 25 and 32 % went home from school/work after 
a SH and 20-26% remained at home the day after the episode. In the same study it was 
found that also mild episodes cause people to miss work. About 10% went home the 
same day and from 2-9% stayed at home the following day. Furthermore hypoglycemia 
reduces productivity and increases healthcare costs. In a review by Fiddler et al. the 
increase in cost varied among the studies depending on the severity of the episode and 
the type of cost studied from €63 for a mild hypoglycemia to €3917 for a severe 
hypoglycemia (78).  
 
2.4 FEAR OF HYPOGLYCEMIA 
Because of the negative affect that hypoglycemia can have on a person’s health, it is 
easy to comprehend why individuals develop fear of hypoglycemia. Of all the 
complications and adverse events related to diabetes, hypoglycemia, together with 
vascular complications, is the most feared complication among people with type 1 
diabetes (79). A recent study by Anarte Ortiz et al. (80) found a 45% prevalence of 
FOH in this group. FOH has been widely studied, but, except for the study by Anarte 
Ortiz, prevalence numbers are hard to find in the literature. This circumstance may be 
due to FOH being such a complex problem that, although measurable, it has been 
difficult to establish a clinical definition of what constitutes excessive or pathological 
fear. 
 
2.4.1 Impact of FOH  
It is well documented that FOH can have a severe impact on those affected, including 
negative consequences for QoL, diabetes management, metabolic control, subsequent 
health outcomes and increased fear and anxiety (40, 58, 81-84).  
 
Worrying about having an episode of hypoglycemia or the consequences of an 
episode is common and can affect the ability to remain attentive to daily activities 
such as work and social engagements, and thus affect an individual’s QoL. Some 
individuals develop panic attacks and agoraphobia related to hypoglycemia (83), 
which can lead to generalization of anxiety problems to other stimuli with severe 
avoidance as a result. Common avoidance behavior include abstaining from exercise, 
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using public transportation and being alone in a variety of situations. Self-
management is often affected, with some individuals using SMBG excessively, 
whereas others completely rely on their own internal cues instead of using SMBG to 
verify a suspected hypoglycemia which often results in overtreatment. Raising one’s  
glucose to a ”safe” level by decreasing the insulin dose or by overeating are strategies 
used to handle FOH, but this may lead to negative consequences in terms of 
heightened risk of long-term complications (58).  
  
FOH does not only affect the person with diabetes but also parents, spouses and next 
of kin (81, 85-89). Relatives of patients with recurrent SH are affected psychosocially 
by sleeping problems and worry about hypoglycemia. FOH can also contribute to 
conflicts in a relationship (85, 89-90). 
 
2.4.2 Measurement of FOH – the Hypoglycemia Fear Survey 
The most widely used instrument to measure FOH, both clinically and for research 
purposes is the Hypoglycemia Fear Survey (HFS), a self-report measure developed by 
Cox and colleagues (40) in the US. The instrument was originally designed for 
individuals with type 1 diabetes with chronically high BG levels resulting from FOH. 
The questionnaire has been translated into over 50 languages (91). HFS has been 
shown to be a valid instrument for use in various populations (92-93) including 
individuals with type 1 and type 2 diabetes (94). The validity has also been confirmed 
by measuring FOH in children with diabetes (CHFS), (95) as well as FOH in parents of 
children with diabetes (PHFS), and in spouses (81, 86-87). According to the authors 
(39) HFS is also suitable for studying a variety of facets of FOH such as the 
phenomenological experience of the fear response, events triggering fear, both adaptive 
and maladaptive behavioral reactions to hypoglycemia and physiological outcomes.  
 
The first version of HFS (HFS I) consists of two subscales with a total of 27 items 
measuring behavioral and affective aspects of FOH. The Behavior subscale (sometimes 
referred to as the Avoidance subscale) consists of 10 items that measure an individual’s 
behavior in his or her effort to avoid hypoglycemia or the effects of hypoglycemia. The 
second subscale (Worry), measuring the emotional/affective aspect of FOH, consists of 
17 items describing a person’s concerns of hypoglycemia and its consequences. The 
items are rated on a five-point Likert scale ranging from Never (1) to Always (5). 
Scoring is done by adding item responses and both subscale scores and a total HFS 
score can be calculated. 
 
The HFS I was later revised and four items removed from the Worry subscale (96) 
leaving 13 items. The Likert scale was also changed to range between 0 (Never) to 4 
(Always), yielding a total score from 0-92. In Bradley’s “Handbook of Psychology: A 
guide to psychological measurment in diabetes research and management”,  (39) this 
23 item version is referred to as HFS II. This is the version that was later translated 
into Swedish and psychometrically evaluated in study II.  
Because the first version of the HFS was developed specifically to assess FOH in 
persons with high BG levels that were due to FOH, the Behavior subscale has been 
shown to be less valid in measuring avoidance behavior in other subgroups of patients 
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especially when the risk of hypoglycemia is high. A largely revised 33-item scale, HFS 
II was therefore developed, but was not psychometrically evaluated until recently (91). 
This version was not available to us in the four studies. The HFS II has a completely 
revised Behavior subscale with 15 items, out of which 10 are new. Five of the items in 
the old version were removed and the remaining items revised. In the Worry subscale 
one item was revised and five new items were added.  
 
2.4.2.1 Psychometric properties of HFS 
Reliability of the HFS has been measured using test-retest reliability and Cronbach’s 
alpha for internal consistency. According to Streiner (97) the alpha level should be at 
least 0.70-0.80 for use in basic research and 0.90 when the instrument is used 
clinically. If alpha is too high this may indicate that some items are redundant. In 
three studies (96, 98-99) the reliability for the Worry subscale was high (alpha=0.89-
0.96) while reliability of the Behavior subscale in two studies (96, 99) was moderate 
(alpha=0.60-0.69) and in one (98) high (alpha=0.84).  
 
Test-retest reliability has been found to be moderate to high (correlations from 0.59-
0.76) for both subscales (100). 
 
The validity of the scale has been explored thoroughly (39) for concurrent, 
postdictive, discriminant and external validity.  Several studies have shown good 
concurrent validity between HFS and different measures of anxiety (98-99, 101), 
confirming that HFS actually measures psychological fear. In the first psychometric 
evaluation of the HFS (40) the authors performed as a validation of construct 
(postdictive validity), a covariation of HFS-score and HbA1c-level. It was predicted 
that responses on HFS would identify individuals with high HbA1c. This analysis was 
able to correctly identify 70% of the HbA1c cases with 6 behavior items and 9 worry 
items. According to the authors this outcome suggests that HFS may be useful in 
differentiating between clinically different levels of HbA1c yet, there was no direct 
correlation between HFS and HbA1c in this study. HFS has also been shown to be 
sensitive to change after interventions. A 6-week program designed to improve 
awareness of hypoglycemia reduced the HFS score significantly from 66 (± 16.1) to 
55 (±14.8), (92).  
 
2.4.2.2 Alternative measures of FOH 
Although HFS is globally a valid and reliable measure of FOH, other instruments 
capturing this problem are available. For example, measures of diabetes related distress 
also include questions that either directly or indirectly assess FOH, such as in the 
Problem Areas in Diabetes (PAID), (102), the ATT39, (103) and finally the Fear of 
Complications Questionnaire (FCQ). However, these instruments cover different and 
wider constructs than HFS. New specific measures of FOH have recently been 
developed for children, the Children’s Hypoglycemia Index (CHI), (104) and for adults 
Fear of Hypoglycemia 15-item scale (FH-15), (80). FH-15 is a self-assessment scale 
containing 15 items rated on a five-point Likert scale (1-5). It consists of three factors: 
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Fear, Avoidance and Interference. The scale shows good psychometric properties and 
provides a cut-off score for FOH. 
 
2.4.3  Predictors and correlates of FOH 
Early models designed to explain FOH and its role in the management of diabetes 
pointed to a linear relationship suggesting that the experience of hypoglycemia first 
triggered fear, followed by avoidance of hypoglycemia, which resulted in poor 
glycemic control (96), (figure 1.). 
 
Figure 1. Early model of FOH in relation to glycemic control, from Handbook of 
Psychology: (39) 
 
 
 
 
 
According to the authors of HFS (39) the model is too simplistic and disregards risk 
of future episodes, degree of perceived distress of hypoglycemia, propensity to 
experience anxiety and how adequately one responds to hypoglycemia. FOH has been 
found to be variable over time as it may increase or decrease depending on the 
perceived or actual hypoglycemia risk (82).  Several studies have found a strong link 
between SH and FOH, suggesting that the experience of hypoglycemia plays an 
important role in triggering FOH (40, 58, 98, 105-106). This possibility is not 
surprising in that SH for most people would be frightening in view of the symptoms 
and possible consequences. There is also evidence that non-severe hypoglycemia 
increase fear in nearly 40% of people with type 1 diabetes (77). Because intensive 
insulin treatment is associated with an increased incidence of  hypoglycemia, 
including severe episodes (8) FOH may also have increased since the adoption of 
intensive insulin therapy as standard treatment for type 1 diabetes. Other links 
between FOH and disease-specific factors include variability in BG level and length 
of time since first insulin treatment (58, 98), as well as reduced hypoglycemic 
awareness (107). High scores on Worry subscale of HFS is associated with difficulty 
in discriminating between early symptoms of hypoglycemia and anxiety (101). This 
can lead to inappropriate responses by the person, leaving a hypoglycemia untreated, 
increasing the risk of a SH, or treating symptoms of anxiety as hypoglycemia and 
thus unintentionally raising the glucose level. 
 
Not everyone who experience SH or who is at risk of SH experience FOH. Moreover, 
fear exists in people with low risk of SH, suggesting that other factors play a role in 
the development of FOH. Concerning psychosocial factors, previous studies have 
found evidence for a link between FOH and trait anxiety (98, 101, 108) which is an 
inclination to easily become fearful or to interpret stimuli as being dangerous (109). 
In Irvine et al. (99) a correlation was present between HFS and phobic anxiety as 
measured in SCL-90. A later study by Irvine et al. (98) confirmed the association with 
phobic anxiety and also showed a correlation with anxiety. In this study interpersonal 
sensitivity, paranoia and psychoticism were related to the HFS-Worry subscale. The 
Behavior subscale was correlated with the somatization subscale of SCL-90. In 
 
Hypoglycemia  Fear (worry)  Avoidance behavior  Elevated BG level         
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Polonsky et al. (101) a hierarchal regression analysis revealed a significant 
association between HFS-Worry and trait anxiety as well as general fearfulness. 
There are also studies showing a link between FOH and extreme fear of self-injecting 
and fear of self-testing (110) as well as to social fear (111). 
 
In the study by Irvine et al. (98) a relationship between hypoglycemic events and 
FOH was found using both HbA1c and a measurement of risk of hypoglycemia based 
on reported BG. Self-reports of hypoglycemia in the previous year were related to the 
Behavior subscale. Fear was significantly lower for individuals with a high mean BG 
(low risk of hypoglycemia), whereas the highest level of FH was seen in those with 
high glucose variability and low mean BG levels. The authors conclude that the data 
support the hypothesis that FOH increases with risk of hypoglycemia. Although many 
correlates of FOH have been reported, more research is warranted on factors involved 
in the development and maintenance of FOH. 
2.4.4 Treatment 
 
Treatment interventions specifically aimed at reducing FOH based on CBT or patient 
education are just beginning to develop, but there are few interventions specifically 
designed to reduce FOH.  There is support that interventions aimed at decreasing the 
risk of SH also decreases FOH (112-113). A psychoeducational program called Blood 
Glucose Awareness Training (BGAT) has been found to reduce worry about 
hypoglycemia (92). The primary aim of this training program is to help individuals 
improve their awareness of their current BG level by teaching them how to recognize 
their best internal cues of high and low BG levels. Another important aim is to gain 
knowledge of those circumstances (e.g. exercise and type of food) that lead to hyper- 
or hypoglycemia, in order to improve prediction of extreme BG-levels. BGAT 
consists of 8 weekly sessions given in group format (5-15 participants per group). 
The participants are taught how to identify their most useful internal cues of extreme 
BG levels as well as how to anticipate these BG levels with information on insulin, 
food and exercise (114). Several studies have shown BGAT to improve accuracy in 
the general detection of current BG level as well as specific detection of hypo- and 
hyperglycemia (115-116) with the largest effect found for those with reduced 
hypoglycemic awareness (114). 
 
In a case-study by Boyle et al. (117) a patient with panic attacks triggered by FOH 
was successfully treated with CBT interventions consisting of exposure to low BG 
and cognitive restructuring. However, to date no larger trials have been performed 
where this treatment is evaluated. The development and evaluation of treatment 
interventions aimed specifically at reducing FOH are therefore greatly needed. 
 
2.5 BEHAVIORAL MEDICINE INTERVENTIONS FOR TYPE 1 DIABETES 
 
A number of interventions within the field of behavior medicine have been developed 
and evaluated relative to improvement in glycemic control and psychological health for 
adults with type 1 diabetes. Some of these interventions are based on educational 
programs, some are based on specific psychotherapies including psychodynamic 
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therapy, CBT, cognitive-analytic therapy, and (multisystemic therapy), whereas some 
are centered on specific tools such as stress management or problem solving (in 
reviews often considered as CBT interventions). Another category referred to is 
counseling in which motivational interviewing is often included. Most interventions 
were given in a group format (118). 
 
A meta analysis found a 0.22% decrease in HbA1c levels for psychological 
interventions in type 2 diabetes (119). In a systematic review and meta-analysis of 
psychological interventions for glycemic control in adult type 1 diabetes 11 studies 
were identified out of which 7 were CBT-interventions. This meta-analysis found no 
significant pooled effect size for improvement of glycemic control. The study also 
showed that the average duration of follow-up was short, (mean 7.2 months, SD ± 4.8) 
(118).  The only psychological intervention showing a long-term decrease in HbA1c is 
a study by Ismail et al.. in which motivational enhancement therapy + CBT showed a 
significant decrease in HbA1c at a 12 month follow-up (120). 
 
Three studies on different CBT-interventions of interest to the design of the CBT 
program in study I are presented below.  
 
The effect of stress management and relaxation training on glycemic control and 
mood was evaluated in a Swedish randomized controlled trial (RCT) (121) with the 
rationale that there is a link between stress and glycemic control. The intervention 
consisted of 14 weekly 2-hour group sessions. Participants were taught stress 
management, muscle relaxation techniques, mental imaging and mental goal-setting 
techniques. In addition they were encouraged to practice these techniques daily at 
home. One year after completing the intervention positive mood changes were found 
with the participants being more satisfied, happy, optimistic, self-confident and 
expressing a more positive social orientation. There were no significant changes in 
HbA1c but those who participated less frequently in the group sessions showed 
significantly worse HbA1c values on all three measurement points.  
 
In an RCT by Karlsen et al. (122) a nine-session CBT intervention delivered in group 
format was evaluated with respect to diabetes-related stress, coping and psychological 
well-being as well as for metabolic control. The program lasted 12 months, with six 
sessions given in the first 6 months. The first four sessions were given in a 2-week 
interval followed by a 2-month break after which an additional two sessions were 
given. The seventh and eight sessions were then given with a 2-month interval 
followed by a 4-month break before the final session was given. Each session lasted 
90 minutes. The focus of the sessions was on conscious reflection, cognitive 
restructuring, problem-solving skills and skills in decision making through group 
discussions and demonstration. The results indicate a significant reduction in 
perceived stress, a more active approach in regulating diabetes, less self-blaming in 
relation to diabetes management and more optimism regarding diabetes. No 
significant reduction in HbA1c was found. 
 
In a Dutch RCT (123) the effect of a CBT program on glycemic control, diabetes self-
efficacy and well-being in type 1 diabetes patients in persistent poor glycemic control 
was evaluated. The study compared a 6-week cognitive behavior group therapy 
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(CBGT) with BGAT as control condition. CBGT focused on cognitive restructuring 
and individual goal-setting. Themes of the six sessions were individual goal-setting, 
the role of cognition and emotions in diabetes self-care, stress, worrying about 
complications, diabetes and interpersonal relationships, diabetes management as 
teamwork. The intervention was successful in improving self-efficacy and diabetes-
related distress and mood, but not in improving glycemic control at a 3-month follow-
up. 
 
To summarize; CBT-interventions show promising results for improvement in 
psychological variables in type 1 diabetes, but there is a lack of convincing evidence 
regarding long-term improvement in glycemic control (122-123).  
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3 AIMS 
 
3.1 GENERAL AIMS 
The general aims of this thesis were to evaluate a cognitive behavior therapy 
intervention for poorly controlled individuals with type 1 diabetes and to explore fear of 
hypoglycemia in order to gain a deeper knowledge of possible targets for interventions 
to reduce fear of hypoglycemia, thereby making it possible to achieve as good self-care 
and glycemic control as possible. 
 
3.2 SPECIFIC AIMS 
 
3.2.1 Study I 
 
The aim of study I was to examine the impact of the CBT-based intervention on HbA1c, 
self-care behavior and psychosocial factors in adult persons with poorly controlled type 
1 diabetes. 
 
3.2.2 Study II 
 
The aim of study II was to evaluate the psychometric properties of a Swedish version of 
the Hypoglycemia Fear Survey (Swe-HFS) in a population of Swedish individuals with 
type 1 diabetes.  
 
3.2.3 Study III 
 
The aim of study III was to examine fear of hypoglycemia and its association with 
demographic and disease-specific variables in individuals with type 1 diabetes.  
 
3.2.4 Study IV 
 
The aims of study IV were to examine the role of emotional and psychosocial factors in 
relation to FOH in individuals with type 1 diabetes and to investigate possible 
differences in these factors in subgroups of persons with high or low FOH having either 
experienced severe episode(s) of hypoglycemia in the past year or not as well as 
subgroups of persons with high or low FOH having either good or poor glycemic 
control, in order to explore possible targets for interventions to reduce FOH.   
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4 THE STUDIES 
 
A general description of the aim, design, inclusion criteria and patient characteristics of 
the four studies is given in table 1 and an overview of the statistical analyses and the 
measurements are summarized in tables 2 and 3. Each study is then described in more 
detail. Data collection for this thesis took place during 2005-2006 for study I, 2006 for 
study II, 2008 for study III and 2010 for study IV.  
 
 
 
 Study I Study II Study III Study IV 
Study aim Evaluation of 
efficacy of a 
CBT-based 
group 
intervention for 
poorly controlled 
adult  with type 1 
diabetes  
Psychometric 
evaluation of a 
Swedish version 
of the HFS 
Examination of 
FOH and its 
association with 
demographic 
and disease-
specific 
variables 
Examination of 
the role of 
emotional and 
psychosocial 
factors in 
relation to FOH 
Design  Randomized 
controlled 
prospective trial  
Methodological  
research design  
Cross-sectional 
descriptive study  
Cross-sectional 
descriptive study 
Inclusion 
criteria 
Type 1 diabetes, 
duration ≥ 2 
years, age 18-
65 years, BMI < 
30 kg/m2, HbA1c 
> 7.5% 
Type 1 diabetes, 
duration ≥ 2 
years, age ≥18 
years 
Type 1 diabetes, 
duration ≥ 1 
years, age ≥18 
years 
Type 1 diabetes, 
duration ≥ 1 
years, age ≥18 
years 
Sample   Consecutively 
recruited 
patients 
identified in the 
local diabetes 
registries of two 
hospitals in 
Stockholm 
Patients 
identified in the 
local diabetes 
registry at the 
Diabetes Care 
Unit, Danderyd 
Hospital 
Patients 
identified in the 
local diabetes 
registries of two 
hospitals in 
Stockholm  
Participants who 
responded to 
study III  
Sample size  94  546 1387  764  
Patient 
characteristics 
    
Gender, % 
Female  
51.4 48 50.3 50.5 
Age (years)  41.2 (12.3) 47.7 (14.7) 41.4 (13.6) 47.0 (14.0) 
Duration of 
diabetes (years) 
21.6 (10.8) 24.0 (13.0) 26.3 (13.9) 31 (14.2) 
Data are m = means and (sd) = standard deviation 
 
Table 1. Characteristics of the studies in the thesis.
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4.1 MEASUREMENTS 
An overview of the measurements used in the four studies is given in table 3.  
 
 
 Study I Study II Study III Study IV 
HbA1C X  X X 
HFS X X X X 
Swe-PAID-20 X X   
HADS X   X 
Questionnaire of 
hypoglycemic events 
  X X 
SDSCA X    
W-BQ 12 X    
SPS    X 
ASI    X 
PSS X   X 
FCQ    X 
Questions of alcohol & 
exercise habits 
   X 
 
 
 
Statistical analysis 
 
Study I 
 
Study II 
 
Study III 
 
Study IV 
Descriptive statistics X X  X X  
Unpaired t-test   X X  X X  
Cronbach’s alpha coefficient X  X  X  X  
ANCOVA X     
MANCOVA X    
Chi-square-test  X X  X  
Principal component analysis  X    
Spearman’s rank-order 
correlation 
  
X  
  
Item-analysis   X    
Inter-correlations matrix  X     
Multiple linear regression 
analysis 
  X X 
ANOVA     X  
Table 3. Overview of measurements used in the studies.
Table 2. Overview of the statistical analyses used in studies I - IV.
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4.1.1 HbA1c 
 
HbA1c was used as an outcome measurement in study I and measured as a clinical 
characteristic in studies II-IV. HbA1c reflects the average BG level during the past 8-12 
weeks. In the present four studies HbA1c was measured and reported using the Swedish 
Mono-S method. In study I HbA1c was analyzed with filter paper technique (HbA1c via 
post) at Karolinska University Laboratory, using an immunological assay developed by 
Roche (normal <5.2%) (124). In studies II-IV HbA1c was analyzed by a 
chromatographic method (study II normal <5.2%, studies III-IV normal <5.0%). 
 
4.1.2 The Hypoglycemia Fear Survey (HFS) 
 
In all four studies the HFS was used to measure FOH. The self-assessment scale, 
originally developed by Cox et al.., (40), was translated into Swedish and in study II 
this version was psychometrically evaluated. The HFS is the most widely instrument 
used to measure FOH and it has been translated into several other languages. The HFS 
consists of two subscales containing 23 items rated on a five-point Likert scale, 0 
(never) to 4 (always). The total sum score could range from 0-92. A higher score 
indicates higher fear. The HFS Worry subscale includes 13 items measuring anxiety 
provoking aspects of hypoglycemia and the HFS Behavior subscale includes ten items 
measuring behavior done in order to avoid hypoglycemia or the consequences of 
hypoglycemia. In all studies the 23-item HFS was used. In study III the 20 item Swe-
HFS was used in the analyses. 
 
4.1.3 The Problem Areas In Diabetes (Swe-PAID-20) 
 
The Problem Areas in Diabetes questionnaire (125) measures diabetes related 
emotional distress and can also be used for discovering depressive symptoms in 
patients with diabetes (126). Swe-PAID-20 (127) was used in studies I - II. It comprises 
20 items each measuring a separate area of diabetes-related distress. The items are rated 
on a five-point Likert scale where 0= not a problem, 1 = minor problem, 2= moderate 
problem, 3= somewhat serious problem and 4= serious problem. The total score (0-
100) is attained by summing up the 0-4 responses for the 20 items and multiplying the 
sum by 1.25. In study I Swe-PAID-20 was used pre- and post-intervention as an 
outcome measure because it has been shown to be sensitive to change when performing 
interventions including medical, educational and psychological components (128). In 
study II Swe-PAID-20 was used to test the convergent validity of Swe-HFS. 
 
4.1.4 The Hospital Anxiety and Depression Scale (HADS) 
 
The Hospital Anxiety and Depression Scale (HADS) (129) is a 14-item questionnaire 
that was developed in order to measure depression and anxiety in patients in somatic 
care. It consists of two subscales, depression and anxiety, each with seven items. The 
items are graded on a four-point Likert scale ranging from 0-3. A Swedish version of 
HADS is available; it has been translated and psychometrically tested (130). The total 
score for the HADS depression scale ranges from 0-21. The total score for the HADS 
anxiety scale also ranges from 0-21. 
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4.1.5 Questionnaire on hypoglycemic events 
 
In studies III and IV a questionnaire with items concerning disease-specific factors 
including frequency and severity of hypoglycemic events (daytime and nocturnal), 
unawareness of hypoglycemia, pharmacological treatment and daily self-monitoring of 
blood glucose (SMBG) were used (131). In study IV only 10 of the 21 questions were 
used. Patients were instructed to answer the questions in regard to the last 12 months. 
In the questionnaire “mild hypoglycemia” was defined as “a sense or premonition that 
your level of glucose is low. It can be reversed by eating fruit or something sweet”. 
“Moderate hypoglycemia” was defined as “fully developed symptoms of 
hypoglycemia. The symptoms increase in numbers and in intensity. It can be reversed 
by eating sugar, drinking milk, sometimes several times. You can by yourself actively 
reverse the hypoglycemia”. “Severe hypoglycemia” was defined as leading to “an 
altered state of consciousness or unconsciousness. You cannot reverse the state on your 
own, but require assistance from another person.”  
 
“Hypoglycemic unawareness” was defined as a plasma glucose value < 4.0 mmol/l 
without ability to perceive symptoms of hypoglycemia.   
 
4.1.6 The Summary of Diabetes Self-Care Activities (SDSCA) 
 
To measure self-care activities the two-item subscales on general diet, specific diet, 
exercise and BG testing of the revised SDSCA were used (132). In addition, two items 
on medication and hypoglycemia were used from the Diabetes Self-Care Inventory 
(DSCI), (133). The items measure the frequency of the given activity during the past 
week. A higher score indicates a higher frequency of the self-care activity. The items 
are scored individually and no sum-score is given. An example of the wording of an 
item is “How many of the last SEVEN DAYS have you followed a healthful eating 
plan?” 
 
4.1.7 The Well-Being Questionnaire (W-BQ12) 
 
To measure well-being in four dimensions we used the Well-Being Questionnaire (39) 
which includes 12 items divided into three four-item subscales: “negative well-being” 
(items 1-4), “energy” (items 5-8), “positive well-being” (items 9-12) and the fourth 
dimension “general well-being” is measured adding the sum scores for each subscale 
(0-12), giving a total score from 0-36.  
 
4.1.8 The Social Phobia Scale (SPS) 
 
Social Phobia Scale (SPS), developed by Mattick & Clarke (134), is a 20-item 
questionnaire measuring anxiety in different social situations. The items are rated on a 
five-point Likert scale ranging from 0 (does not apply to me) to 4 (applies completely 
to me). The total score for the SPS ranges from 0-80. 
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4.1.9 The Anxiety Sensitivity Index (ASI) 
 
The Anxiety Sensitivity Index (ASI) (135) measures fear of anxiety-related symptoms. 
The questionnaire has 16 items rated on a five-point Likert scale ranging from 0 (not at 
all) to 4 (very much). The total score for the ASI ranges from 0-64.  
 
4.1.10 The Perceived Stress Scale (PSS) 
 
The Perceived Stress Scale (PSS) is a questionnaire used to measure how stressful 
different situations in one’s life are appraised (136). The scale, developed by Cohen 
and colleagues has 14 items measured on a five-point Likert scale (0 = never, 4 = 
always except item 4-7, 9, 10 & 13 where 0 = always, 4 = never). There is a Swedish 
version psychometrically tested by Eskin (137). The total score for the PSS ranges from 
0-56. 
 
4.1.11 The Fear of Complications Questionnaire (FCQ) 
 
The Fear of complications questionnaire (FCQ) is a 15-item questionnaire designed to 
measure fear of diabetes complications. The items are rated on a four-point Likert scale 
ranging from 0 (never) to 3 (always) (138). We have translated the scale in to Swedish. 
The total score for FCQ ranges from 0-45. 
 
4.1.12 Alcohol and exercise habits 
 
Alcohol and exercise habits were measured in study IV when exploring possible 
psychosocial factors related to FOH.  
 
Alcohol habits were measured using the first two questions from AUDIT, The Alcohol 
Use Disorders Identification Test (139). The questions were “How often do you drink 
alcoholic beverages?” and “How many “glasses” of alcohol do you drink on a typical 
day when consuming alcohol?” 
 
Exercise habits were measured with three questions regarding frequency and intensity 
of exercise previously used in a report on exercise habits and health among adults in 
Sweden (140). 
 
4.2 STUDY I 
 
4.2.1  Design and procedure 
Before the RCT was implemented, a pilot study with six participants tested and 
supported the feasibility of the intervention. Subjects who fulfilled the inclusion criteria 
received information about the study by mail and were contacted one week later by 
telephone to confirm the inclusion and exclusion criteria. If the interview confirmed the 
criteria, the subject was asked to participate in the study and those who accepted the 
invitation received a set of self-report questionnaire. When the questionnaires were 
completed and returned to the clinic the randomization process took place manually 
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with a person not involved in the study. The randomization, done in blocks of 16 
participants, (eight each in the intervention and control) was gender-stratified in order 
to receive mixed groups of females and males. The intervention group received the 
CBT-based group treatment and the control group received continuous glucose 
monitoring (CGMS) on two occasions. Both groups remained in contact with the 
diabetes care team as usual. 
 
4.2.1.1 Assessments 
Demographic and clinical data (age, sex, diabetes duration, cohabitation, education, 
paid job, HbA1c, BMI, total amount of insulin/kg, diabetes complications and insulin 
therapy) were retrieved from medical records. The primary outcome variable glycemic 
control, measured with HbA1c was assessed at baseline and weeks 8, 16, 24, 32, 40 and 
48. The secondary outcome variables, reflecting self-care behavior (SDSCA), diabetes-
related emotional effects (Swe-PAID 20, HFS) and general emotional effects (W-BQ12, 
PSS, HADS) were assessed at baseline and at weeks 12 (only SDSCA), 24 and 48.  
 
4.2.2  Participants 
Participants in study I were recruited from the diabetes care units of two university 
hospitals in Stockholm, Sweden. Inclusion criteria were diagnosis of type 1 diabetes, 
age 18-65 years, diabetes duration ≥ 2 years, BMI < 30 kg/m2, HbA1c > 7.5% (ref 5.2%) 
during the past year. Exclusion criteria were insufficient reading and comprehension 
skills, pregnancy, diagnosed psychiatric illness or alcohol or drug abuse, and ongoing 
intercurrent disease. Information on inclusion and exclusion criteria was gathered 
through medical records and confirmed in a telephone interview. Of the 230 subjects 
who fulfilled the criteria, 122 declined to participate. Of the 94 participants recruited 
consecutively to either the intervention group or the control group, 15 never entered 
any of the study arms leaving 40 participants starting the CBT-program and 39 the 
control group with routine care and CGMS.  
 
4.2.3  Intervention  
 
4.2.3.1 Rational for the CBT-program 
Because previous studies on CBT for type 1 diabetes have failed to show (long-term) 
improvement of glycemic control (122-123) our research group looked at possible 
reasons for this and designed the program based on experience from interventions in 
similar areas of behavior change intervention (10). It was hypothesized that earlier CBT 
interventions were too brief and without a structured follow-up program. Furthermore, 
although having several advantages, the group format used previously lacked the 
possibility of individualising the intervention to fit each participant’s unique needs. A 
possible lack of focus on behavioral components was also observed. The present 
intervention therefore emphasized the importance of self-care activities in achieving 
glycemic control and tools designed to facilitate behavior change in this area were on 
this basis introduced early and used throughout the whole intervention. The tools to 
facilitate self-management included a diary of self-care activities and stressful 
emotions, continuous glucose monitoring (CGMS) and a problem-solving technique. 
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A structured maintenance program was added and the theme of “relapse” and “relapse-
prevention” was introduced in the basic intervention program. Individual sessions were 
included both in the basic program and in the maintenance program to facilitate 
behavior change for each participant. Furthermore, feedback on homework was not 
only given orally during the session but also in writing to each individual in the 
following session. 
 
4.2.3.2 Outline of intervention 
The CBT-intervention was mainly given in a group format with 4-6 participants in each 
group and included a basic 8-week program and a structured maintenance program 
lasting from week 9 to week 42. The intervention was led by a psychologist trained in 
CBT and a diabetes specialist nurse.  
 
The basic program consisted of 8 weekly sessions lasting 2 hours with the main 
purpose of mapping the participants’ self-care behavior and possible barriers to 
metabolic control. All sessions except session seven were given in a group format. 
 
The maintenance program started 1 month after the basic program and included two 
group and two individual sessions as well as four telephone calls. Focus was on follow-
up of the participants’ goals and action plans. The outline of the program, including 
themes and tools used can, be found in table 4. 
 
4.2.3.3 Outline of each session 
Each session followed the same basic outline and was centered on a specific theme 
related to living with diabetes. It began with a short version of Applied Tension Release 
(ATR) (see description below) followed by a follow-up of the past week’s homework. 
A fair amount of time was spent on the homework and each participant was encouraged 
to share his or her experience. Following the homework was a brief introduction to the 
theme of the session (e.g. stress or anxiety). The introduction was given by the 
psychologist (or sometimes the diabetes specialist nurse) in a psycho-educative format. 
To facilitate discussion and sharing of experiences a fictive case was then presented 
and discussed. When applicable, problem solving was used to create solutions for 
problems presented in the case. A new tool specifically chosen for the theme of the 
session (for instance, the tool exposure when the theme was anxiety and worry) was 
then presented and discussed with the participants. Finally, homework for the following 
week was given to the participants. In addition to the log book and practice in ATR, the 
homework usually consisted of applying or trying the new tool introduced in the 
session. 
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Table 4. Outline of the CBT-intervention 
Study‐
week 
Session  Theme  Tools and homework 
 
  Basic 
program
   
1    1 (G)  How does diabetes affect 
my life? 
Log book for self‐care behavior and 
stressful emotions. Interaction model. 
ATR (long version)
2    2 (G)  Stress and diabetes  Log book, CGMS, Identifying negative 
thoughts, Problem solving, ATR (long 
version)
3    3 (G)  Stress and diabetes 
continued 
Log book, Biofeedback ‐ feedback on 
CGMS, handling negative thoughts, 
ATR (short version)
4    4 (G)  Diabetes complications 
and the future
Log book, Coping with worries/anxiety, 
Exposure, ATR (short version) 
5    5 (G)  Family and friends  Log book, Assertiveness training, ATR 
(quick version)
6    6 (G)  Values in life.  Log book, Values and goals in life,  ATR 
(short version)
7    7 (I)  Goal‐setting and plan for 
behavior change  
Individual action plan and goal‐setting 
 
8   8 (G)  Maintaining behavior 
change. Handling relapse
Log book, Set‐back vs relapse 
 
  Maintenance 
program 
  During the maintenance program, tools 
were adapted to fit the need of each 
individual in relation to the planned 
behavior change. Common tools were 
problem solving, behavior activation 
and replanning of goals. 
    9 (T)  Evaluation of individual 
plan of behavior change.
 
12  10 (I)  Evaluation of individual 
plan 
 
12  11 (G)  General follow‐up of 
group members. Sharing  
experiences of difficulties 
and success
 
16  12 (T)  Same theme as session 9  
20  13 (T)  Same theme as session 9  
24  14 (I)  Same theme as session10   
24  15 (G)  Same theme as session11  
32  16 (T)  Same theme as session 9  
42  17 (T)  Same theme as session 9  
G = Group session, I = Individual session, T = Telephone call 
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4.2.4 Tools used in the CBT-intervention 
 
A number of tools were used in the program. Below, a description and rationale of each 
tool is given.  
 
4.2.4.1 Log book of self-care behavior and stressful emotions 
Participants were strongly encouraged to use daily the log book of self-care behavior 
and stressful emotions provided in the program. The log book was introduced during 
the first session and was thereafter used as a recurrent homework assignment each 
week. The participants were asked to perform and log a number of self-care behavior 
that included SMBG before and 30 minutes after each meal. They were also asked to 
log the injected insulin-doses and to rate and log their meals according to how well it fit 
with recommendations, to log any incidence of hypoglycemia and to log exercise 
(duration and type). In addition to self-care behavior, they were also asked to rate (on a 
five-point Likert scale) their experiences for each day of a number of stressful emotions 
such as irritation, hurry and sadness. There were two main purposes of the log book. 
Firstly it was a tool to explore self-management behavior and barriers by increasing 
awareness of patterns in the participants BG levels. Secondly therapist’s prompting of 
and attention to the log book was intended to reinforce the participants’ new active 
strategies, in an effort to help them gain experiences of being able to influence BG 
levels. The log-book is shown in figure 2.  
 
 
Figure 2. Picture of log-book used in the CBT intervention 
 
4.2.4.2 Continuous Glucose Monitoring  – delayed biofeedback 
Biofeedback is a method in which technology is used to allow an individual to gain 
awareness of, and control over, physiologic processes. In research the method has been 
shown to be beneficial for several stress-related and pain conditions, as well as for other 
forms of somatic problems (141). Usually, the method employed gives the individual 
instant physiological feedback on a specific behavior. In this study the participants were 
provided with a continuous glucose monitoring system (CGMS Gold, Medtronic 
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Minimed Northridge, CA, USA) serving as a delayed biofeedback of glucose levels on 
two occasions, during the inclusion and during session 2. CGMS measures interstitial 
fluid glucose values every 5 minutes often for three consecutive days through a 
subcutaneous sensor placed in the abdomen. Interstitial glucose closely mirrors blood 
glucose values. During the measurement period the participant cannot directly see the 
glucose level: instead, a glucose profile is given after the period is over. While using 
the CGMS the participants were instructed to log various behaviors in the device as 
well as in a log book, including insulin injections, meals, exercise, hypoglycemic 
episodes and other important activities. After the 3-day period the participants returned 
to the diabetes specialist nurse to download the data to a computer. In addition, graphs 
representing the glucose levels along with the relevant behavior during this period were 
plotted and printed out for the participant. On the first occasion, the participant received 
feedback directly by the diabetes specialist nurse. On the second occasion, i.e. during 
the basic program, the participant received the graphs with the instruction to reflect on 
them and report on this during the next session (session 3) in which feedback also was 
given by the diabetes specialist nurse and the psychologist. The purpose of this 
intervention was to help participants reflect on patterns between self-care behavior and 
glucose levels. The control group also received CGMS on two occasions but without 
any direct feedback from medical staff. They were given the graphs and were informed 
that they could consult their diabetes nurse for feedback if they wished. The CGMS is 
shown in figure 3 and an example of a 3-day glucose profile in figure 4. 
 
 
Figure 3. Continuous Glucose Monitoring Systems (CGMS®),  
Medtronic MiniMed (Northridge, CA) 
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Figure 4. An example of a 3-day glucose profile provided by the CGMS 
 
4.2.4.3 Problem-solving 
According to a systematic review, improvements in HbA1c were found in over 50% of 
interventions using some sort of problem-solving technique (142). A six-step problem-
solving technique was therefore introduced in the first session and thereafter used 
throughout the program as a method of generating active coping strategies to problems. 
The steps in the technique are:  
 
1. Define the problem  
2. Generate solutions  
3. Evaluate the solutions  
4. Select a solution(s) 
5. Plan the implementation of the solution and follow through with it  
6. Evaluate - how effective was the solution in solving the problem? 
 
4.2.4.4 Applied Tension Release 
ATR (143-144) is a development of applied relaxation, (145) a widely used and 
researched coping method for anxiety disorders (146-147) as well as within the field of 
behavioral medicine (148). Two components serving separate purposes are the building 
stones of ATR; the quick tension release skill with the aim of decreasing unnecessary 
tension at any given time and situation, and a longer skill (5-20 minutes) with the aim 
of increasing the ability to achieve a deeper relaxation serving as recovery. The 
rationale for using ATR was to give the participants a portable tool to reduce stress 
(both long-term and acute stress) in that stress may have a direct or indirect effect on 
blood glucose as well as on well-being.  
 
In the CBT-program the participants were provided with a CD with instructions for 
ATR. They were instructed to practice ATR daily, both the quick tension release and 
the longer skill, beginning by listening to the CD and gradually shifting to self-
instructions. The ability to self-instruct is important for the tool to become portable. 
Also each session was started with ATR. 
 
4.2.4.5 Identifying and handling negative thoughts and emotions 
It is well documented that experiencing negative thoughts and emotions related to 
diabetes is common and may have a negative impact on self-care behavior and mood 
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(125, 149). An A-B-C model (Antecedent, Behavior, Consequences) (150) was 
therefore used to help participants identify and handle negative thoughts and emotions. 
Participants were instructed to be aware of negative thoughts and emotions occurring 
(B), what situations/stimuli seemed to trigger (A) these negative reactions, how the 
participant handled the situation (B) and the short- and long-term consequences (C) of 
these actions. They were then encouraged to challenge the negative emotions and 
thoughts by acting differently in order to change the negative consequences of their 
original response. 
 
4.2.4.6 Exposure  
Strong support is available suggesting that exposure is a powerful tool in the treatment 
of anxiety disorders (151). A number of fears and anxiety problems are related to 
diabetes; fear of hypoglycemia (40), fear of self-injecting (110, 152), fear of vascular 
complications (79) and generalized anxiety disorder (153).  As a method to overcome 
these fears and problems, exposure was introduced in session 4. The purpose of 
exposure is to create new experiences of the feared stimuli by approaching instead of 
avoiding or fleeing from them (154). The mechanism of exposure has previously been 
thought to be fear reduction (154) but more recent research has indicated that fear 
tolerance might be at least as important (155).  
 
In the CBT program, exposure was not directly used during the session. Rather the 
participants were encouraged to identify a fear and to implement exposure of this fear 
as a homework assignment. Participants were taught the principles of exposure and 
how to create a hierarchy of feared stimuli. 
 
4.2.4.7 Assertiveness training – communication skills 
The rationale for teaching assertiveness is that effective communication skills are 
important in receiving the help and support needed from medical personnel as well as 
family and friends. Three ways of communicating (passive, aggressive and assertive) 
were illustrated through role play by the therapists. Participants were encouraged to 
practice assertive communication during a session as well as between sessions. Time 
was taken to discuss possible situations in which assertive communication could be of 
use to each participant. 
 
4.2.4.8 Values in life 
The theme in session 6 was values and goals in life. This theme was included to 
promote motivation for behavior change. Working with values has been fruitful in 
improving glycemic control in type 2 diabetes (156) as well as in psychiatric problems 
(157) and other somatic problems such as chronic pain (158). The discussion during 
session 6 was introduced by telling a story with a metaphor about prioritizing. The 
participants were given the worksheet “Goals and Values” as homework. 
 
4.2.4.9 Goal-setting and action plan 
During the individual session in the basic program (session 7) each participant in 
collaboration with either of the two therapists decided on 1-2 goals for behavior change 
based on barriers most often discovered during sessions 1-6. Setting goals for behavior 
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change has been shown to improve self-management skills in individuals with diabetes 
(159). Goals were discussed using questions such as “Why is this change important to 
me?”, “What would be different in my life if I reach my goal?”, “What do I need to do 
in order to reach my goal?”, “What barriers are there in reaching this goal and how can 
I handle them?” There was an emphasis on reaching the goal(s) in a stepwise manner 
planning for intermediate goals at set dates with the knowledge that a lasting behavior 
change takes time (197). Strategies to reach the goals were formulated in a written 
action plan given both to the participant and the therapist for use during the 
maintenance program. 
 
4.2.5  Analysis 
 
Statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). For 
demographic and clinical characteristics, descriptive statistics were used. Differences 
between the intervention and control groups were assessed by unpaired t-tests and for 
categorical variables chi-square tests. An intention-to-treat analyses, with all 
participants entering the intervention (n = 40) and control group (n = 39) after the 
randomization and with values at a given follow-up point, was the preferred analyses 
strategy. These analyses thus included five participants who withdrew from the study, 
four from the intervention and one from the control group. 
 
For the primary variable HbA1c, a multivariate analysis of covariance (MANCOVA) 
was performed with the values of weeks 8-48 entered as the dependent variables, and 
“group” was entered as independent variables. Covariates in the model were the results 
of HbA1c at baseline, sex, BMI and duration of diabetes. Data were imputed for a total 
of six participants at one or several weeks using the expectation-maximization (EM) 
algorithm. Post-hoc analyses were performed each week using analysis of covariance 
(ANCOVA) with the same covariates as in the MANCOVA. Between-group effect 
sizes were calculated using Cohen´s d to compare the intervention group and the 
control group at 8, 24 and 48 weeks and within-group effect sizes from pre-treatment to 
weeks 8, 24 and 48. Standard deviations of raw scores based on baseline data were used 
in the calculations as suggested by Feingold (160). 
 
For the secondary variables ANCOVA was performed at weeks 12, 24 and 48 with the 
same covariates as in the analysis of the HbA1c results. 
 
4.2.6  Results 
 
There were no significant differences at baseline between the intervention and control 
group. Baseline HbA1c was 8.4% for the intervention group and 8.5% for the control 
group. For the 36 participants who completed the CBT-program the average attendance 
was 6.8 sessions of the 8 sessions in the basic program and 3.6 sessions of the 4 
sessions in the follow-up program. 
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4.2.6.1 Primary outcome 
A significant difference in HbA1c was found between the intervention and control group 
at all assessment points from week 8 onwards. The largest difference appears at week 
24. Table 5 shows data on HbA1c including effect sizes not previously published. 
 
4.2.6.2 Secondary outcome 
Significant differences were found in secondary outcome variables throughout weeks 
12 to 48. At week 12 self-care activities were measured and a significant difference was 
found for SMBG with the intervention group showing a higher frequency than the 
control group. This difference was maintained at weeks 24 and 48. At week 24 there 
were also significant differences between groups in incidence of hypoglycemia, 
diabetes-related distress and negative well-being with the intervention group reporting a 
higher incidence of hypoglycemia, lower diabetes-related distress and less negative 
well-being. These differences were maintained at week 48. Furthermore significant 
differences on general well-being, perceived stress, anxiety, depression and avoidance 
of hypoglycemia were found at week 48 for the intervention group which showed 
improvements in all these outcome measures.  
 
Table 5. Means and SDs as well as within-group and between-group effect sizes              
(Cohen’s d) for HbA1c before intervention, after the basic treatment program (8 weeks)                     
and at weeks 24 and 48. 
Assessment 
point (week) 
Intervention 
n=36    mean 
(SD) 
Control   n=38    
mean (SD) 
   Within‐group effect size  
Intervention           Control 
Between‐group 
effect size 
0  8.46 (0.86)  8.47 (0.81)       
8  7.58 (1.00)  8.25 (1.16)  1.02   0.27  0.75 
24  7.50 (0.71)  8.44 (1.50)  1.12   0.04  1.08 
48  7.72 (1.21)  8.21 (1.27)  0.86   0.32  0.54 
 
 
4.2.7  Comment   
 
The evaluation of the CBT intervention showed significant improvements in glycemic 
control, self-management and psychological factors, with the effect being largest at 24 
weeks. Although the between-group effect size at 48 weeks was moderate, the HbA1c 
reduction was > 0.5% which is considered clinically important in reducing the risk of 
long-term complications. This is one of the first studies showing such a significant and 
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long-lasting effect on HbA1c. A limitation of the study was the small sample size which 
did not allow a formal mediator analysis of change in HbA1c.  
 
 
4.3 STUDY II  
 
4.3.1  Design and procedure 
 
The original HFS, consisting of 23 items was translated into Swedish using a forward-
backward translation method (97). The translated version was sent by post to 546 
participants along with the Swe-PAID-20. One written reminder was sent after 2 weeks 
to those participants who did not return the questionnaire. After that, no further action 
was taken. For the purpose of content analysis, the questionnaire was sent to an expert 
panel of ten diabetes specialist nurses at three university hospital located in Stockholm, 
Sweden.  Each expert was asked to rate the relevance of each item on a four-point scale 
(from 1 = “not at all relevant” to 4 = “very relevant”). A concluding question was 
inserted at the end of the questionnaire to evaluate their opinion on the relevance of the 
total scale on a four-point scale (from 1 = “do not agree at all” to 4 = “do agree 
totally”). 
 
Demographic and clinical characteristics of the participants were taken from medical 
records and included information on age, sex, cohabitation, education level, duration of 
diabetes, treatment regimen, data on long-term complication and the latest HbA1c value. 
 
4.3.2 Participants 
 
The participants in the psychometrical evaluation were patients with type 1 diabetes 
having a duration of two of more years and age ≥18 years, identified in the local 
diabetes registry at the Diabetes Care Unit, Danderyd Hospital, Stockholm, Sweden. 
The participants were excluded if they had insufficient reading and comprehensive 
skills or if they were diagnosed with alcohol or drug problems or psychiatric illness. In 
all 1070 possible participants were identified.  To enable a factor analysis of HFS at 
least 230 participants were required (23 items *10 participants per item) (161) and a 
total of 546 participants received the questionnaire with HFS and Swe-PAID-20. To 
avoid differences that were due to metabolic control the sample was divided according 
to HbA1c level ≤ 7.5% and HbA1c level >7.5% (ref <5.2%). Thereafter the participants 
were systematically randomized from these two groups. 
 
4.3.3  Analysis  
 
Data analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistical tests were employed for demographical and clinical 
characteristics of the participants. Unpaired t-tests were used for comparison of 
demographic data between responders and non-responders. Missing values on the HFS 
and PAID were corrected using the method prescribed by Polit and Beck (161). For the 
missing items the most typical responses based on the mean were computed.  
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The content validity ratio (CVR) for the total instrument was the proportion of items 
rated as 3 or 4.  A CVR score of 0.80 or better indicates good content validity (162). To 
determine construct validity of the scale a principal components analysis (PCA) was 
performed of the 23-item HFS scale. Varimax rotation was used to extract the 
components with the assumption that subscales were independent of each other. A 
loading level of 0.50 was chosen for the items to be included in a component. An item 
analysis was conducted in order to assess how well each individual item related to other 
items in the subscale. Correlations of 0.40 or higher are generally recommended and 
correlations below 0.30 regarded as unacceptably low (163). 
 
The reliability of the scale was measured using Cronbach’s alpha coefficient for the 
total score as well as for the possible subscales. Cronbach’s alpha is a measure of 
internal consistency or, in other words, to what extent all items measure the same 
construct. Correlations are recommended to range from 0.70 – 0.80 if the instrument is 
used to compare groups, and preferably  > 0.90 when the instrument is used for clinical 
applications (164). 
 
To test the convergent validity, the HFS was compared with the Swe-PAID-20 using 
Spearman’s rank-order correlation. The correlation coefficient r, reflects whether two 
measures capture the same construct. Measures within a similar domain should 
therefore correlate from r = 0.40 - 0.80. A lower correlation indicates that the measures 
capture different constructs or that one of the measures has an unacceptably low 
reliability (97). It was hypothesized that the HFS and Swe-PAID-20 would show a 
moderate correlation in that both scales measures diabetes-related distress with the HFS 
measuring a specific distress and Swe-PAID-20 measuring more general distress.  
 
4.3.4  Results 
 
4.3.4.1 Clinical and demographic data 
Totally 324 participants returned the questionnaire yielding a response rate of 60%. 
Comparing responders with non-responders showed a significant difference regarding 
age with responders being older (mean 47.8 ± 14.7) than non-responders (mean 42.5 ± 
14.0), p < 0.01. No significant differences were found for sex or HbA1c. Two patients 
were identified as outliers when conducting frequencies for the scale and were therefore 
excluded, leaving 322 respondents for analysis. 
 
4.3.4.2 Psychometric evaluation 
The PCA showed unsatisfactory support in the factor loadings for the original two-
factor solution which consisted of the Behavior-subscale and the Worry-subscale. With 
a two-component solution five items did not load in any of the components (items 1, 2, 
5, 8 and 12). Instead a three-component solution was indicated in the analysis with 
component 1 (Worry) having an eigenvalue of 6.4 and accounting for 28% of the 
response variance, component 2 (Behavior) having an eigenvalue of 2.3 (accounting for 
10% of the response variance) and component 3 (Aloneness) having an eigenvalue of 
1.5 (accounting for 6.4% of the response variance). These three components together 
accounted for 44% of the variance. Three items (1, 8 and 12) were excluded because 
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they did not load on any of the three components, leaving only 20 of the initial 23 items 
in the total scale.  
 
The exclusion of the three items led to a change in the scoring of the scale with the 
score for the total Swe-HFS scale ranging from 0-80, the Worry-subscale with 10 items 
ranging from 0-40, the Behavior-subscale with 6 items ranging between 0-24 and for 
the Aloneness-subscale with 4 items ranging from 0-16. For the 322 participants in this 
study the score for Swe-HFS-total ranged from 3 to 55. The scores for the total scale as 
well as the subscales are shown in table 6.  
 
The convergent validity was measured by correlating the Swe-HFS with the Swe-
PAID-20. The total Swe-HFS correlated positively with the total Swe-PAID-20 (r 
=0.44, p = 0.01), as did the Worry-subscale (r =0.50, p < 0.01) and the Aloneness-
subscale (r =0.22, p < 0.01). The correlation between the Behavior-subscale and the 
total Swe-PAID-20 was not significant (r =0.09, p > 0.05), however.  
 
The content validity ratio between the expert panellists ranged from 0.8 -1.0 except 
for 2 items, nr 3 with a ratio of 0.1 and nr 12 with 0.6. Of the 23 items measuring fear 
of hypoglycaemia, all but one item, nr 3 “If test blood glucose, run a little high to be 
on the safe side”, were judged to be quite relevant or very relevant by the expert 
panellists. Evaluating the last summing question concerning the relevance of the total 
HFS, 7 nurses out of 10 totally agreed, and 3 out of 10 agreed to a certain extent that 
the total HFS scale was relevant.  
 
Regarding reliability of the Swe-HFS, Cronbach’s alpha for the entire scale was 0.85 
and 0.63-0.89 for the subscales (table 6). The inter-item correlation analysis showed 
that all items in two of the components, (Worry and Aloneness) had correlations 
between 0.40 and 0.70 (p <0.01). The items in the Behavior subscale had significant 
but lower correlations (0.10-0.40). Corrected item-total correlation ranged from 0.49 to 
0.76 for the items in component 1 (Worry), from 0.29 to 0.46 for the items in 
component 2 (Behavior) and from 0.40 to 0.65 for the items in component 3 
(Aloneness). Component 2 showed the poorest corrected item-total correlation, with 
only one item with r > 0.4. The five remaining items had r from 0.29-0.39. Removing 
individual items lowered Cronbach’s alpha, indicating that they belong to each subscale 
and thus all items were retained. 
 
Table 6. Scores and Cronbach’s alpha for the Swe-HFS total and for the subscales 
  
Mean (item) score 
(SD) 
 
Cronbach’s alpha 
 
Swe-HFS total  
 
25.0 (1.25) (± 10.8) 
 
0.85 
 
Swe-HFS Worry 
   
  9.0 (0.90) (± 7.1) 
 
0.89 
 
Swe-HFS Behavior 
 
12.3 (2.05) (± 10.8) 
 
0.63 
 
Swe-HFS Aloneness 
  
  3.1 (0.78) (± 10.8) 
 
0.73 
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4.3.5  Comment  
 
The Swedish version of the HFS was found to be valid and reliable in measuring FOH. 
The instrument showed satisfactory internal consistency and convergent validity. The 
PCA did not support the two-factor structure found in the original HFS but instead 
found a three-factor solution being optimal with the third factor reflecting FOH and 
avoidance of situations in which one is alone. There may be cultural as well as 
methodological issues underlying this difference in factor structure. 
 
 
4.4 STUDY III 
 
4.4.1 Design and procedure 
 
Study III was a survey study exploring the association between FOH and demographic 
and disease-specific factors in which the participants were asked to reply to a set of 
questionnaires. The Worry subscale and the Aloneness subscale of the Swe-HFS 
previously evaluated in study II were used to measure FOH. A 21-item questionnaire 
on frequency and severity of hypoglycemic events, unawareness of hypoglycemia, 
pharmacological treatment and frequency of SMBG in the past 12 months were also 
included in the set of questionnaires (131). Demographic and disease-specific data (e.g. 
gender, age, duration of diabetes and HbA1c) were obtained from medical records. The 
median value of all recorded HbA1c values in the past 2 years was used. 
 
4.4.2 Participants 
 
The participants in study III were identified in the local diabetes registries of two 
university hospitals in Stockholm, Sweden. A total of 1387 participants fulfilled the 
criteria of type 1 diabetes with a duration of ≥ 1 year, onset before 30 years of age and 
age ≥ 18 years of age. All participants received a set of questionnaires by mail, 
including a prepaid return envelope. A reminder was sent after 2 weeks to those 
subjects who did not return the questionnaire. No further action was taken after that. 
 
4.4.3 Analysis 
 
Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). 
Demographic and clinical characteristics were analyzed using descriptive statistics. 
Missing values were imputed using the expectation-maximization algorithm in the 
SPSS module for missing data. Overall, the rates of missing values were low, being 
below 1.2% with the exception of item 19 (“Having a reaction while driving”) which 
had 6.9% missing values. Analyses of differences between groups were made with 
either the Chi-square test or the unpaired t-test. 
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Multiple linear regression analyses were used to explore the possible relationship 
between the two HFS subscales and demographic and disease-specific factors. The 
sum-scores of the Worry subscale and of the Aloneness subscale were used as 
dependent variables in the analyses. The independent variables were entered in two 
blocks: block 1 included the demographic variables and block 2 the disease-specific 
variables. In each block forward stepwise regression was applied. Inclusion in the 
model was set at p ≤ 0.05 and exclusion at p ≥ 0.10. Additional regression analyses 
were performed after stratifying for gender. 
 
4.4.4 Results 
 
The response rate was 55% (764 responders) of which 49.7% (380) were men and 
50.3% (384) women. There were significant differences between the responders and the 
non-responders: the responders were older, more often women, had a lower HbA1c 
level and a longer duration of diabetes than the non-responders. 
 
A significant gender difference was found in both the Aloneness and the Worry score 
with women scoring higher than men. Item scores for the Worry subscale and for the 
Aloneness subscale can be found in table 7. 
 
Table 7. Item scores for the Worry and the Aloneness subscales 
 HFS Worry subscale HFS Aloneness subscale 
 n Mean  Median SD 25th * 75th* Mean Median  SD 25th* 75th* 
Men 380 0.81 0.73 0.66 0.27 1.09 0.78 0.50 0.78 0.00 1.25 
Women  384 1.06 1.00 0.75 0.55 1.45 0.90 0.75 0.86 0.25 1.50 
Total 764 0.94 0.82 0.72 0.36 1.27 0.84 0.50 0.82 0.00 1.25 
* Indicates percentile 
 
The regression analysis showed that the Aloneness subscale was significantly 
associated with gender, frequency of SH, frequency of mild hypoglycemia, HbA1c, 
hypoglycaemic unawareness and visits to emergency department due to hypoglycemia. 
Adjusted R2 for the model was 0.136, p-value <0.001. The Worry subscale was 
significantly associated with frequency of SH, number of symptoms during mild 
hypoglycemia, gender, hypoglycemic symptoms during hyperglycemia and 
hypoglycemic unawareness. Adjusted R2 for the model was 0.159, p-value <0.001. 
 
Because of the significant gender difference separate regression analyses for gender 
were performed. For men, the Aloneness subscale was significantly associated with 
frequency of SH, number of symptoms during mild hypoglycemia, HbA1c, hypoglycemic 
unawareness, frequency of moderate hypoglycemia and frequency of SMBG. Adjusted 
R2 for the model was 0.156, p-value <0.001. For women the Aloneness-subscale was 
significantly associated with frequency of SH and number of symptoms during mild 
hypoglycemia. Adjusted R2 for the model was 0.112, p-value <0.001. For men the 
Worry subscale was significantly associated with frequency of SH, number of symptoms 
during mild hypoglycemia and hypoglycemic unawareness. Adjusted R2 for the model 
was 0.145, p-value <0.001. For women the Worry subscale was significantly associated 
with frequency of SH, number of symptoms during mild hypoglycemia and 
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hypoglycemic symptoms during hyperglycemia. Adjusted R2 for the model was 0.119, 
p-value <0.001. 
 
4.4.5 Comment  
 
Frequency of severe hypoglycemia was identified as being the most important factor 
associated with FOH. For the first time, gender differences in FOH were documented 
(females were more affected by FOH than men). Also of importance is the positive 
association found between HbA1c and the Aloneness subscale, indicating that FOH may 
have a negative impact on glycemic control. 
 
4.5 STUDY IV 
 
4.5.1  Design and procedure 
 
Study IV is a survey study exploring the association between FOH and emotional, 
psychosocial, demographic and disease-specific factors. The participants were asked to 
reply to a set of questionnaires that measured these factors. The total HFS scale (23 
items) was used to measure FOH. A 10 item questionnaire on frequency and severity of 
hypoglycemic events, unawareness of hypoglycemia, and frequency of SMBG in the 
past 12 months was also included in the set of questionnaires (131). Emotional and 
psychosocial factors included measures of anxiety and depression (HADS), anxiety 
sensitivity (ASI), social anxiety (SPS), perceived stress (PSS), fear of complications 
(FCQ), and questions on alcohol and exercise habits. Demographic and disease-specific 
data on gender, age, duration of diabetes and HbA1c were obtained from medical 
records. The median value of all recorded HbA1c values in the past 2 years was used. 
 
4.5.2  Participants 
 
All participants (n=764) who responded to study III received the set of questionnaires 
described above by mail. The participants were previously identified from local 
diabetes registries of two university hospitals in Stockholm, Sweden. Inclusion criteria 
for the study were type 1 diabetes, age of onset < 30 years of age and duration of 
diabetes ≥1 year. A reminder was sent after 2 weeks to those persons who did not 
return the questionnaire. No further action was taken after this. 
 
4.5.3 Analysis 
 
Statistical analysis was performed using PASW 18.0 (SPSS Inc., Chicago, IL, USA). 
Demographic and clinical characteristics were analyzed using descriptive statistics. 
Missing values were imputed using the expectation-maximization algorithm in the 
SPSS module for missing data. Overall, the rates of missing values were low with the 
exception of item 19 (“Having a reaction while driving”) which had 7.4% missing 
values. Analyses of differences between groups were made with either the Chi-square 
test or the unpaired t-test. 
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Multiple linear regression analyses were performed to explore the possible relationship 
between the total HFS-score and demographic, disease-specific, emotional and 
psychosocial factors. The sum score of the total HFS scale was used as the dependent 
variable in all the analyses. The independent variables in the regression models were 
entered in three blocks with block 1 containing the demographic variables and block 2 
the disease-specific variables and block 3 the emotional and psychosocial variables. In 
each block forward stepwise regression was used. Inclusion in the model was set at p ≤ 
0.01 and exclusion at p ≥ 0.05. Separate regression analyses were performed after 
stratifying for gender. Data were checked for multicollinearity using the variance 
inflation factor < 4 and tolerance values > 0.20 as the criterion level. To validate the 
models we analyzed the standard residuals checking for normal distribution. It turned 
out that the HFS scale fitted the normal distribution. Measuring the internal consistency 
Cronbach’s alpha for the HFS total scale was 0.89, HFS Worry  0.92, HFS Avoidance 
0.69, PSS 0.82, HADS total 0.91, Anxiety subscale 0.83, Depression subscale 0.80, SPS 
0.93, ASI 0.90, and FCQ 0.94.  
 
Group differences were analyzed using the unpaired t-test, chi-square test or ANOVA. 
Statistical significance was set at p < 0.05. Two sets of subgroup analyses were 
performed to explore factors associated with FOH. In both sets high FOH was defined 
as those participants scoring ≥ 75th percentile, and low FOH as those participants 
scoring ≤ 25th percentile on the total scale of the HFS.  
 
The first set of subgroups was then divided into two groups reflecting risk of SH.” High 
risk of SH” was defined as those participants who experienced severe episode(s) of 
hypoglycemia in the past year and “low risk of SH” was defined as those who did not 
experience SH in the past year. The subgroup of patients with high FOH and low risk 
of SH was labeled phobic fear; the subgroup of patients with high FOH and high risk 
of SH was labeled appropriate fear; the subgroup of patients with low FOH and low 
risk of SH was labeled appropriate disregard; and the subgroup of patients with low 
FOH and high risk of SH was labeled denial. 
 
The second set of subgroups was divided according to HbA1c level: high HbA1c was 
defined as ≥7.5% and low HbA1c as ≤ 6% (reference value <5%). 
 
4.5.4  Results 
 
In this study 469 participants responded (232 women and 237 men) giving a response 
rate of 61%. As in study III there were some minor differences between responders and 
non-responders, the responders being slightly older with a longer duration of diabetes 
and having somewhat lower HbA1c. 
 
The regression analysis showed a significant positive association between the total 
score of HFS and frequency of SH, gender, frequency of nocturnal hypoglycemia, 
frequency of SMBG, number of symptoms during mild hypoglycemia, ASI, the anxiety 
subscale of HADS and SPS. Adding the emotional and psychosocial variables to the 
model increased the R2 from 0.16 to 0.39. 
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After stratifying for gender the regression analyses showed some differences regarding 
the association between HFS and emotional and psychosocial factors. ASI was 
associated with HFS for both men and women whereas FCQ was associated with HFS 
only for women. 
 
The subgroup analyses of the first set based on risk of SH showed the subgroup effect 
to be significant for all emotional measures and for number of symptoms during mild 
hypoglycemia and HbA1c. For all emotional measures the two groups with high fear 
(phobic fear and appropriate fear) reported higher scores than the two groups with low 
fear (denial and appropriate disregard). The group of participants with phobic fear 
reported a higher frequency of symptoms during mild hypoglycemia than the two 
groups with low FOH. HbA1c was higher in the group with appropriate disregard than 
the group with appropriate fear. The group with appropriate fear showed the highest 
frequency of nocturnal and daytime SMBG as well as the highest frequency of 
“moderate” and “nocturnal hypoglycemia” of “hypoglycemia unawareness” and of 
“visits to the emergency department”. The group with phobic fear evidenced the 
highest frequency of “hypoglycaemic symptoms during hyperglycemia” as well as 
“frequency of symptoms during mild hypoglycemia” and the lowest frequency of 
alcohol consumption. 
 
For the second set of subgroup analyses based on HbA1c level the subgroup effect was 
also significant for all emotional measures and for “number of symptoms during mild 
hypoglycemia”. The two groups with high FOH had significantly higher scores on all 
emotional measures compared with the groups with low FOH. “Frequency of 
symptoms during mild hypoglycemia” was significantly higher in the group with high 
FOH/high HbA1c than in the group with low FOH/low HbA1c. The group with high 
FOH/ high HbA1c reported fewer SMBG than the group with high FOH/ low HbA1c. 
The group with high FOH/ low HbA1c showed the highest frequency of SH. 
 
4.5.5  Comment  
 
This study showed that FOH was positively associated with the emotional factors: 
anxiety, fear of anxiety symptoms and social phobia. The results support the gender 
differences found in study III as well as the importance of frequency of severe 
hypoglycemia in FOH. The study also demonstrated differences between the different 
subgroups of participants on factors associated with FOH that may have implications in 
developing interventions. 
 
4.6 SUMMARY OF THE RESULTS OF THE HFS 
 
The Hypoglycemia Fear Survey was used in all four studies. Table 8 summarizes the 
HFS mean scores in studies I-IV, as well as for all four studies combined. In total, 1629 
HFSs have been completed and all four studies showed that women scored significantly 
higher than men. 
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Table 8. Summary of HFS mean scores (SD) and item mean scores for studies I-IV.  
Score   Study I  Study II Study III Study IV  All studies
n  74  
(m=36, f=38) 
Mean (SD) 
324 
(m=169, f=155)
Mean (SD)
764 
(m=380, f=384)
Mean (SD)
467 
(m=232, f=235) 
Mean (SD) 
1629 
(m=817, f=812) 
Mean (SD)
HFS       
     Total   30.2 (13.9)  30.73 (12.54) 33.39 (14.06) 31.83 (13.91)  32.27 (13.71)
     Item     1.21 (0.60)    1.34 (0.55)   1.45  (0.61)   1.38  (0.60)    1.40  (0.60)
HFS 
Behavior 
         
     Total   17.3 (6.1)  18.1 (6.01) 18.50 (5.71) 18.48  (5.91)  18.36 (5.84)
     Item     1.73 (0.61)    1.81 (0.60) 1.85  (0.57)   1.85  (0.59)    1.84  (0.58)
HFS Worry           
     Total   12.9 (9.5)  12.64 (8.82) 13.36 (9.83) 13.36  (10.02)  13.20 (9.67)
     Item      0.94 (0.73)    0.97  (0.68) 1.03 (0.76)   1.03 (0.77)    1.02 (0.74)
HFS 
women 
         
     Total 
  
33.7* (14.0)  34.43*** 
(12.39)
35.95*** 
(14.57)
33.90** 
(14.39) 
34.96*** 
(14.08)
     Item   11.47 (0.61)    1.50 (0.54) 1.56 (0.63)   1.47 (0.63)    1.52 (0.61)
HFS men           
     Total   26.5* (12.9)  27.35*** 
(11.73)
30.79*** 
(13.03)
29.74** 
(13.10) 
29.59*** 
(12.78)
     Item   11.15 (0.56)    1.19 (0.51) 1.34 (0.57)   1.29 (0.57)  1.29 (0.56)
* p <0.05, ** p = 0.001, *** p < 0.001, f= female, m= male  
   
4.7 ETHICAL CONSIDERATIONS 
 
The studies were conducted in accordance with  the ethical principles of the 
Declaration of Helsinki (165) and the ethical codes of the Swedish Psychological 
Association, (166). The studies in this thesis were approved by the Regional Ethics 
Committee, Karolinska Institutet, Stockholm, Sweden (Study I Dnr 2006/91-32, 03-
396, Study II Dnr 2005/1401-31/2) and by the regional ethical review board (studies III 
and IV, Dnr 2006/1069-31/2). The participants in study I were informed verbally and in 
writing and the participants in studies II-IV were informed in writing only. All 
participants gave their written informed consent to participate and were free to 
withdraw at any time.  
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5 GENERAL DISCUSSION 
 
The general aims of this thesis were to evaluate a cognitive behavior therapy 
intervention for poorly controlled individuals with type 1 diabetes and to explore fear of 
hypoglycemia in order to gain a deeper knowledge of possible targets for interventions 
to reduce fear of hypoglycemia, thereby making it possible to achieve as good self-care 
and glycemic control as possible. 
 
5.1 THE CBT INTERVENTION 
 
In study I, the CBT program showed promising results with significant improvements 
in glycemic control, self-care behavior and psychological factors. The program was 
successful in improving the participants HbA1c by > 0.5% (-0.78%) which is considered 
clinically important in decreasing the risk of long-term complications (8). In this thesis 
between-group and within-group effect sizes are presented for the first time. We found 
a large within-group effect size at 8, 24 and 48 weeks and a moderate between-group 
effect size at 48 weeks. This was one of the first studies of its kind that demonstrated 
such significant and long-lasting effects of CBT. Similar results were found in a study 
by Ismail et al. (120) published within the same time frame, (although in their study 
there are no data on effect size). In this comparison between individual motivational 
enhancement therapy (MET) with, or without CBT, with traditional care for 
participants with type 1 diabetes with sub-optimal glycemic control, a significant 
positive effect on glycemic control was found for the combined MET plus CBT group 
compared with the group given traditional care at 12 months follow-up. The reduction 
in HbA1c was -0.46%. However, no significant difference was obtained for outcome of 
depressive symptoms, FOH, self-care, QoL and BMI.  
 
We do not know which parts of the intervention were of importance in improving 
HbA1c but a plausible contention is that the focus on self-management behavior and 
SMBG was important. The result showed an increased frequency of SMBG at 12 
weeks and further on in the intervention group. Regular use of SMBG is crucial in 
making correct decisions on self-care. Using the log book changed the contingencies 
for the participants and enabled them to have new experiences of being able to 
influence their BG levels. In other words, the behavior to self-test BG was reinforced 
when the participants discovered that they were able to control BG by adapting self-
management to their current BG-level. The support and assistance from the therapists 
in discovering patterns affecting BG may also have been of considerable value. The 
rapid development of systems using continuous glucose monitoring proposes CBT as a 
valuable tool in striving for improved glucose control when this technique is used. In a 
recent study by Kovatchev et al., (167) the effect of automated bio-behavioral feedback 
on glycemic control was studied. The results showed improvement in average glycemic 
control and reduction in moderate or severe hypoglycemia. The largest effect was 
found for individuals who were at highest risk of hypoglycemia at baseline. This study 
supports the hypothesis that attention to self-management is important in improving 
glycemic control. In a recent review by Plack et al. (168) covering studies between 
March 2008 to September 2009, several studies showed support for self-management 
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interventions based on behavior modification techniques combined with diabetes 
education or medical feedback, being effective in reducing HbA1c in type 2 diabetes. 
No RCT’s with adults with type 1 diabetes were found during this time period. 
 
Another possible reason for participants improving in our study may relate to the 
individual sessions given. Such sessions enabled each participant to tailor his or her 
own individual plan and receive one-on-one support in the behavior change process. 
Individualized plans and one-on-one support are often necessary because of several 
limitations to the group format. One limitation is the generality of help usually given in 
group. Many participants may have problems individualizing or translating this help so 
that it is applicable to his or her situation. Another limitation is that group sessions do 
not provide enough time for everyone to raise his or her issues on a deeper level. 
Further some individuals hesitate to talk about their problems in a group setting, but 
may be able to address them in an individual session with only the therapist present. 
Support for individualization was found in Ismail et al. (120). The participants in this 
study who received individual therapy, improved glycemic control. On the other hand, 
the participants in a study by Snoek et al., comparing two group interventions did not 
(169). This study compared CBT and BGAT in patients with poorly controlled type 1 
diabetes. The CBT intervention was effective in lowering HbA1c up to 1 year of follow-
up, but only in a subgroup of participants with high baseline depression scores. There 
were significant improvements in the total sample for both interventions for depressive 
symptoms, self-care, diabetes-related distress and self-efficacy but, as stated above, not 
for HbA1c.  
 
Although the participants in the intervention group improved or maintained their well-
being and psychological health, including FOH, the increase in frequency of 
hypoglycemia reported in the intervention group requires further study. The data show 
that participants decreased their avoidance behavior in relation to hypoglycemia 
whereas no difference was found on the Worry subscale. Baseline measures show that 
our sample scored higher on the Behavior subscale than on the Worry subscale which 
indicates the use of avoidance behavior in relation to hypoglycemia. This observation 
signals the need for future interventions to focus on preventing an increase in frequency 
of hypoglycemia by teaching the participants the skills to appropriately handle lower 
BG-levels. The above mentioned study by Kovatchev et al. (167) supports this 
argument, showing that a decrease in HbA1c without an increase in frequency of 
moderate or severe hypoglycemia is possible to achieve when automated feedback is 
given on BG-levels. 
 
In an additional study (not included in this thesis) that evaluated the CBT program we 
aimed to find predictors and associations of improved glycemic control but no clear 
results were found in the analyses (170). This may be due to the sample size being too 
small and the design of study I not being done with analyses of predictors in focus.   
 
Study I took place in 2005-2007 and a natural question would be to ask whether the 
improved glycemic control still persists today, i.e. whether our maintenance program 
was successful over the long run. We have no such data available; however, a recently 
published 4-year follow-up (171) of the study with MET+CBT (120) revealed 
discouraging results. The follow-up was able to assess 75% of the participants in the 
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original study. No significant differences in glycemic control between the control group 
and any of the two intervention groups were noted 2 and 4 years post-intervention. This 
intervention however, did not include a maintenance program. Another study including 
adolescents aged 14 to 16 years involved an intervention consisting of a ‘‘personal 
trainer’’ using principles of motivational interviewing, applied behavior analysis and 
problem solving for problems in diabetes management. The study reported a 
significant reduction in HbA1c at a 24-month follow-up (172), suggesting that a long-
term change is possible to achieve. In this intervention, as in our intervention, 
telephone calls were made in addition to six individual sessions over a 2-month 
period.  
 
An economic evaluation of this program would have been of importance in order to 
completely evaluate the feasibility of this intervention. The intervention by Ismail et 
al.’s (120) in which participants received MET+CBT did not indicate that the program 
was cost-effective (173). This intervention however, was done on an individual basis 
and thus most likely more costly than a group intervention.  
 
5.1.1  Methodological considerations 
 
The present study has some methodological limitations and considerations that must be 
addressed. First, the relatively small sample size limits the conclusions that can be 
drawn from this study. With a larger sample, formal mediator analysis could have been 
performed that could give valuable information in regard to mediators to change in 
glycemic control. 
 
Although the majority of attrition occurred early in the study protocol, the attrition rate 
(24%) together with the fact that over 50% of those who fulfilled the inclusion criteria 
declined to participate, raises concerns about the external validity of the results. On the 
basis of this possibility we can only draw conclusions regarding the results with respect 
to individuals fulfilling the inclusion criteria.  
 
An active control group receiving an alternative, plausible intervention would also have 
added strength to the study by ruling out increased attention as part of the effect. The 
participants were exposed to increased attention for almost 1 year in this intervention, 
although the control group also received increased attention with two occasions of 
CGMS and had the possibility to discuss the results with their diabetes specialist nurse.  
 
 
5.2 PSYCHOMETRIC EVALUATION OF THE HFS 
 
Psychometric evaluation of the Swedish version of the HFS gave evidence for the 
instrument’s validity and reliability to measure FOH in a Swedish population of adults 
with type 1 diabetes. The HFS demonstrated good internal consistency and convergent 
validity. In analyzing the construct validity, no support was found for the original two-
factor structure. Instead a three-factor solution proved most optimal. Moreover, the 
analysis indicated that 3 of the original 23 items not loading on any of the factors, 
leaving 20 of the original 23 items. The third factor detected in this study included 
items reflecting worry about, or behavior related to having hypoglycemia when alone. 
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The factor was therefore named Aloneness. This is the first study to detect a third factor 
in the HFS. The result may be due to differences in language or culture, although being 
alone is a universal condition that might make the consequences of a hypoglycemic 
episode more severe. Other possible reasons for the difference found in the factor 
structures may be that the number of respondents was larger, and different sample 
populations compared with previous studies.  
 
5.2.1 Methodological considerations 
 
Removing three items from the HFS scale is debatable because it increases the risk of 
not discovering certain worries in individuals and also makes comparison with 
international studies more difficult. However, the analysis did reveal that removing 
these three items made the scale more psychometrically robust. 
 
Although the reliability of the Behavior subscale was acceptable in this evaluation, it 
seems to be the weakest link in the HFS, being less reliable and valid than both the 
Worry subscale and the Aloneness subscale. In addition to showing that the internal 
consistency was low, all items in the Behavior subscale had low correlations and low 
corrected item-total correlations. Furthermore, two of the three deleted items belonged 
to the Behavior subscale. A major problem with the Behavior subscale is that it may 
measure multiple dimensions, both appropriate and inappropriate behavior depending 
on the person’s risk of hypoglycemia. The original scale was developed for individuals 
with poor glycemic control. Thus such individuals have a low risk of hypoglycemia. 
When HFS is administered to individuals with a greater risk of hypoglycemia, the 
subscale does not correctly reflect inappropriate avoidance behavior. Earlier findings 
by the original authors support these weaknesses (39-40) and therefore several other 
studies have therefore only used the Worry subscale (41, 92-93, 110). Accordingly, it 
was decided not to use the Behavior subscale in study III. 
 
With the Behavior subscale reflecting behavior appropriate when the risk of 
hypoglycemia is high, a largely revised 33-item scale, HFSII,  was recently 
psychometrically evaluated by Gonder-Frederick et al. (91) and was therefore not 
available to us at the time of study II. This version has a completely revised Behavior 
subscale with 15 items, out of which 10 are new. Five of the items in the old version 
were removed and the remaining ones revised. In the Worry subscale one item was 
revised and five new items were added. In this evaluation the authors found that 
participants with poor metabolic control scored higher on the Behavior subscale. 
Additional findings were that the Worry subscale was more strongly related to mental 
and emotional QoL and the Behavior subscale more strongly related to physical QoL 
(91).  
 
5.3 STUDIES III AND IV 
 
The aims of studies III and IV were to explore factors associated with FOH in order to 
identify possible targets for intervention to reduce fear of hypoglycemia thereby 
making it possible to achieve as good self-care and glycemic control as possible. Study 
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III focused on disease-specific and demographic factors while study IV in addition 
included emotional and psychosocial factors. 
 
Studies III and IV confirm that frequency of SH is the most important disease-specific 
factor associated with FOH. This association is intuitively easy to appreciate as the 
experience of SH often is very frightening, and will therefore likely lead to increased 
fear of another episode. In other words, fear may become conditioned, not only to 
hypoglycemia but also to circumstances of the experience such as the place or time of 
the episode. Also, having recently experienced SH increases the risk of another 
episode, and in that sense makes the fear more appropriate. This is also true for 
“hypoglycemic unawareness” which is an additional factor associated with FOH. The 
association between intensive insulin treatment, tighter glycemic control and an 
increase in frequency of hypoglycemia, including severe hypoglycemia (66, 174) raises 
concern about a possible increase in FOH in persons with this treatment, justifying the 
development of insulin treatments with lower risk of hypoglycemia.  
 
The gender difference (women scoring higher than men) that was found in study III and 
was confirmed in study IV, is a novel finding. Additional analyses of data from studies 
I and II also show women scoring significantly higher than men on HFS. This 
difference also seems to hold with HFS II, as the evaluation by Gonder-Frederick et al. 
(91) found women scoring higher than men. Furthermore, it has been reported that girls 
score higher than boys (108) and yet another study found mothers having higher scores 
than fathers (87). These results are important from a clinical point, but are not 
surprising in that they are consistent with data on anxiety disorders in general (175). 
Why women show higher FOH than men we can only speculate on. Possible 
hypotheses include biological differences, with women in general having a genetic 
predisposition towards being more fearful, as well as cultural aspects i.e. it might be 
more acceptable for women to express anxiety.  
 
The association between HbA1c and the Aloneness subscale noted in study III is 
consistent with previous studies (81, 107, 176) that found FOH to have a negative 
impact on glycemic control. Still other studies (98, 177-179) have not found this result. 
Support for this negative impact of FOH was recently established in a study evaluating 
HFS II (91) with scores on the Behavior subscale being higher in participants with poor 
metabolic control. No difference was noted for the Worry subscale. This may indicate 
that the avoidance behavior, in addition to being effective in reducing hypoglycemia, 
also is efficacious in reducing worry and anxiety, as seen in other anxiety disorders 
(180) and would support operant processes being involved in FOH. For those with 
excessive avoidance that leads to poor glycemic control, identifying and changing the 
specific avoidance behavior are needed. This change will most likely involve exposure 
to anxiety in different ways (of which one would be lower BG-levels). Thus, this group 
may initially experience increased anxiety when not avoiding, but the purpose of the 
exposure is to give them new experiences on how to handle anxiety and lower BG-
levels in an appropriate way so the avoidance becomes unnecessary.  
 
The positive association found between FOH and “number of symptoms during mild 
hypoglycemia” in studies III and IV and with “hypoglycemic symptoms during 
hyperglycemia” in study III may be interpreted as an increased vigilance towards 
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observing symptoms of hypoglycemia. However, the results of the subgroup analyses 
in study IV indicate that this may be true only for the group with “phobic fear”. A 
person who worries about hypoglycemia may be vigilant for symptoms that may 
indicate hypoglycemia and thus be more sensitive to any physical changes, interpreting 
these as signs of hypoglycemia. Vigilance to symptoms of anxiety is a phenomenon 
observed in anxiety disorders (181-182). There is also support for this phenomenon in 
people with type 1 diabetes: Wiebe et al. (183) found an association between trait 
anxiety and an inclination to over interpret non-diabetes-related symptoms as reflecting 
BG levels. That difficulty to interpret symptoms correctly can play a role in FOH was 
shown in Polonsky et al. (101). This study reported a positive correlation between FOH 
and difficulty separating anxiety from early symptoms of hypoglycemia. This difficulty 
can cause problems in two ways: persons can misinterpret symptoms of hypoglycemia 
as anxiety, leading to an increased risk of the hypoglycemic episode becoming severe, 
or they can treat a hypoglycemia that doesn’t exist, resulting in an elevated BG. 
Treating the false hypoglycemia (eating) will be negatively reinforced when the 
symptoms disappear, i.e. increasing the probability that the same behavior will be 
performed next time the symptoms occur.  
 
Although study III showed that frequency of SH was an important factor in FOH 
together with the other disease-specific and demographic factors the model could only 
explain 16 % of the variance in the Worry subscale, leaving a large percentage 
unexplained. Study IV aimed to explain part of this variance by adding emotional and 
psychosocial factors to the model. Concerning the new factors the results showed that 
the total HFS was positively associated with ASI, the Anxiety subscale of HADS, and 
SPS. Adding these factors to the model it explained 39% of the variance vs only 16% 
without these factors. The fact that FOH was positively associated with several 
different measures of anxiety was not surprising because HFS is also a measure of 
anxiety and because several earlier studies have shown strong support for an 
association between FOH and anxiety both in general such as trait anxiety (101, 108) 
and general fearfulness (101) and more specific anxiety problems such as social fear 
(111) and fear of self-injecting and self-testing (110) and panic attacks (184). 
 
Even though anxiety is strongly linked to FOH there are no data suggesting causality in 
any direction. The relationship is most likely bidirectional with some individuals being 
predisposed through a general fearfulness to easily develop FOH, whereas others 
develop FOH after a traumatic experience of hypoglycemia which in turn leads them to 
become more fearful in general. The second alternative was illustrated in a case study 
(83) in which a man developed agoraphobia and panic attacks after experiencing an 
episode of hypoglycemia while driving. Initially he avoided driving but later on the 
worry of having a hypoglycemic episode generalized to many other situations and he 
eventually began to avoid these situations to. He was successfully treated by learning to 
distinguish between symptoms of hypoglycemia and symptoms of anxiety in addition 
to exposure and other methods used in CBT. 
 
In study IV we also performed subgroup analyses on the basis that some individuals 
showed a more appropriate FOH in that their risk of experiencing hypoglycemia was 
high, whereas some had an excessive or phobic FOH in the sense that they had a low 
risk of experiencing hypoglycemia. The hypothesis was that these subgroup analyses 
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would show important differences in what factors were associated with high or low 
FOH. In these analyses having high FOH, regardless of whether the fear was phobic or 
appropriate, was associated with having higher scores on all emotional measures except 
for the HADS depression scale. Especially anxiety, social anxiety and fear of anxiety 
symptoms were higher for those with high FOH. The lack of statistically significant 
differences between the two groups with high FOH was perhaps surprising. It was 
expected that persons in the group with phobic fear would be more anxious than the 
group with appropriate fear because of their reactions being more excessive than the 
reactions of those in the appropriate fear group. On the other hand, it may be argued 
that the high anxiety levels reported for the phobic group is surprising in that they had 
less risk of having SH compared with the appropriate fear group. There were however 
differences between the two groups regarding disease-specific factors. The phobic fear 
group was characterized by a tendency to interpret hyperglycemia as hypoglycemia and 
to report more symptoms during hypoglycemia, whereas the appropriate fear group was 
characterized by a higher frequency of SMBG, hypoglycemic unawareness and visits to 
the emergency department. 
 
There were also some data pointing to a possible difference in handling FOH between 
the group with high FOH/low HbA1c and the group with high FOH/high HbA1c. Those 
with high FOH/high HbA1c reported fewer SMBGs than those with high FOH/low 
HbA1c, implying that the group with high FOH/high HbA1c had an excessive reliance 
on internal and external cues of hypoglycemia instead of verifying their BG-levels 
through SMBG. This would indicate that increasing the frequency of SMBGs may be 
helpful in improving glycemic control for these individuals, although this may not be 
enough. A recent study found that patients with type 2 diabetes had poor problem-
solving skills when detecting hypo- and hyperglycemia through SMBG (185) pointing 
to a need for interventions that facilitate learning of these skills. 
 
The subgroup analyses did not confirm some of the hypothesized differences between 
individuals with “phobic FOH” and “appropriate FOH”. A possible explanation for this 
lack of difference may be that our definitions of the different groups fail to mirror the 
actual risk of experiencing SH. A method that has proven very accurate in risk 
assessment is the logarithm that uses SMBG-data stored in a BG-meter (186). Another 
possible way of assessing risk is to calculate glucose variability using SDBG (187-
189), something that is relatively easy with modern BG meters.  
 
5.3.1 Methodological considerations 
 
In studies III and IV the median value of all recorded HbA1c in the past 2 years was 
chosen as a measure of glycemic control in order to minimize the influence of 
temporary changes. Such a measure enables us to study how FOH relates to glycemic 
control over time. However, because HFS is an instrument sensitive to temporary 
changes such as having a SH, it can be argued that the last recorded HbA1c would have 
been a more valid measure. Thus our results may not accurately reflect glycemic 
control at the time when FOH was measured. In study III the subscales Worry and 
Aloneness found in the psychometric evaluation were used in the analyses. We chose to 
exclude the Behavior subscale because of its limited validity. However, to facilitate 
international comparison we decided to include the Behavior subscale and the three 
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excluded items in the analyses of study IV. Reporting only the HFS total score in Study 
IV may be questioned from a methodological standpoint in that other studies have 
found differences in how psychosocial variables relate to the Worry and Behavior 
subscales (91). Because similar results were found when analyzing the subscales 
separately, reporting only the regression model related to total HFS significantly 
reduced the ample amount of data.  
 
Using 6.0% and 7.5% as cut-off’s for HbA1c in the division of the subgroups good vs 
poor glycemic control is also questionable. One can argue for the use of a split at 6% 
which is the target set for glycemic control instead. The reason for not using this split 
was that we were not primarily interested in the participants who had normal/average 
HbA1c. Rather the more extreme groups with high or low HbA1c were the aim of our 
exploration.   
 
Another questionable decision was the use of the ASI. The ASI measures anxiety 
sensitivity, or fear of anxiety symptoms, and because some of these symptoms overlap 
with symptoms of hypoglycemia it may be said that the instrument is too similar to the 
HFS when used in this group. The choice to include the ASI was made in spite of this 
fact because of the hypothesis that the instrument may be useful in detecting specific 
symptoms relevant as targets for intervention.    
 
A limitation to studies III and IV is that the revised version of the HFS (i.e. HFS II) 
could not be used. This is especially unfortunate in studying the connection between 
glycemic control and FOH in that the new Behavior subscale shows higher validity 
than the old one.   
 
Other limitations include the moderate response rate and significant differences noted 
between responders and non-responders for gender, age, HbA1c and duration of 
diabetes, raising concerns about the external validity of the regression models.  
However, the demographic and clinical differences although statistically significant 
were small and therefore probably of minor importance for the results. Furthermore the 
reports of frequency of hypoglycemia were retrospective and may therefore include 
some measurement error. Finally the moderate R2 limits the predictive value of the 
models.  
 
5.4 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
 
This thesis focused on behavioral barriers to glycemic control in general as well as on 
the barrier of fear of hypoglycemia, and the possibility to overcome them through CBT 
thus improving self-care.  
 
In conclusion, Study I showed that CBT seems to be a promising method to help 
individuals with type 1 diabetes to improve glycemic control and self-care with  
maintained or improved psychological health. The intervention also seems to target the 
barrier of FOH by decreasing avoidance behavior of hypoglycemia without increasing 
worry. However, the increased frequency of hypoglycemia observed, signals that the 
program needs additional focus on promoting adequate self-care actions to different 
BG-levels. Further, we do not know whether the improvements in glycemic control and 
 50 
self-care behavior are lasting effects or disappear after a certain time. With the 
discouraging result from the follow up by Ismail et al. and the knowledge that behavior 
change is vulnerable and in need of support, one may suspect similar results from our 
study. It is however to be noted that our study did include a maintenance program 
incorporating both group sessions as well as individual sessions and telephone calls to 
prevent the loss of treatment effect. Future studies would probably benefit from 
developing maintenance programs further. A possible way to maintain, and over time 
even improve self-management further could be to integrate the intervention with 
regular diabetes care so that health care providers would be able to continue supporting 
the patient in the behavior change process. This approach would require health care 
providers to be trained in the principles of CBT and learning theory. Maisse et al. 
showed that this is possible in that their nurses demonstrated good adherence to 
protocol (190). Another way of providing CBT-based interventions to individuals with 
type 1 diabetes would be to develop Internet-based programs. This format of 
intervention could also provide a possibility to reach individuals who for different 
reasons are unwilling or unable to attend face-to-face interventions. There is support for 
Internet-delivered treatment being effective in psychiatric disorders (191-192) and 
somatic problems (17, 193-194). A fairly recent study in Holland showed that an 
internet based CBT intervention for depression was effective in reducing depressive 
symptoms in type 1 and type 2 diabetes, although the long-term effect of this 
intervention remain unknown (195). 
  
Regarding the barrier of FOH the Swe-HFS proved to be a reliable and valid measure 
in adults with type 1 diabetes. Considering the importance of discovering FOH and the 
relative ease with which the Swe-HFS can be administered it may be a valuable clinical 
tool in assessing FOH. Even though no cut-off score is currently available, the result 
could serve as a basis for discussion of worries and strategies used to avoid 
hypoglycemia. However, with a revised version of HFS, (HFSII), (91) recently being 
psychometrically evaluated showing better psychometric properties, especially for the 
Behavior subscale, a Swedish translation and evaluation of this version is warranted. 
There is also a need to establish norms with a cut-off score indicating problematic 
FOH, as well as values to determine what constitutes clinically important differences. 
Staargardt et al. (94) used  distribution- and anchor-based methods to explore the 
concept of the Minimum Clinically Important Difference for the Worry subscale in 
patients with type 2 diabetes. Such an approach may be a feasible for type 1 diabetes 
as well. Recently a cut-off score was established for the FH-15 (a new scale measuring 
FOH) by using subjective fear as a criterion and a receiver-operating characteristic 
analysis based on Youden’s index (80). Employing this method, items in the scale 
could differentiate patients as either having FOH or not. 
 
Studies III-IV showed that FOH is a complex problem in which previous experience of 
hypoglycemia, along with anxiety, play important roles in the development and 
maintenance of the fear. Vigilance of hypoglycemic symptoms is probably relevant at 
least for the group with phobic fear. There is now a great need to develop and evaluate 
specific interventions aimed at reducing FOH in order to improve self-care, glycemic 
control and health. The two-factor model of fear and avoidance (43) in addition to a 
risk assessment of future hypoglycemia may prove helpful in analyzing individual fear 
and avoidance behavior so that appropriate interventions in FOH can be designed. The 
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individuals with so called appropriate fear (or high risk of experiencing hypoglycemia) 
would probably benefit from interventions aimed at reducing the risk of experiencing 
hypoglycemia, as by modifying insulin therapy with pumps, by automated bolus 
calculators (196) or by real time continuous glucose monitoring systems including 
alarms for hypo- and hyperglycemia. However these individuals may also need help in 
handling anxiety in general. The group of individuals with phobic fear is not primarily 
in need of risk reduction, but instead need to change the strategies they use to avoid 
hypoglycemia. Such persons may be helped through exposure (117) and methods that 
teach them symptom detection as well as appropriate actions to different BG-levels 
such as provided by Blood Glucose Awareness Training or other methods using 
biofeedback, including the use of technical devices for real-time continuous glucose 
monitoring (114, 167). The findings of study I showing participants decreasing their 
avoidance of hypoglycemia and increasing the actual frequency of hypoglycemia 
support the use of these methods being of importance. It would be of interest to 
investigate the relative effect of exposure and methods to teach appropriate self-care 
actions, as well as their combined effect on FOH. 
 
Although CBT seems a feasible method to improve glycemic control, self-
management, mental health and possibly FOH, it is far from clinical reality in Swedish 
diabetes care today. There are unfortunately, very few teams with a psychologist and 
even fewer with competence in CBT. Having a psychologist trained in CBT could 
benefit diabetes care in several ways. In addition to promoting behavior change through 
individual as well as group interventions, the psychologist could assess diabetes-related 
distress and mental health (including FOH) as well as serve as an advisor or tutor to 
other health care professionals in the diabetes care team.   
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6 CONCLUSIONS 
The main findings from the four studies in this thesis are: 
 
• The CBT-intervention shows promising results in improving glycemic control, 
self-care behavior and psychological factors in individuals with poor glycemic 
control. The program is worthy of further evaluation in clinical settings. 
 
• The Swedish version of HFS is a reliable and valid instrument for measuring 
fear of hypoglycemia in a Swedish-speaking population of adult individuals 
with type 1 diabetes.  
 
• Evidence for a strong association between FOH and the frequency of 
experienced SH in the past year is supported. A significant gender difference is 
found with women showing higher FOH than men. 
 
• The associations between FOH and emotional and psychosocial factors are 
complex. A link between anxiety and FOH is confirmed. There is support for 
differences in factors associated with FOH between sub groups of individuals 
with high or low risk of hypoglycemia, indicating the relevance of risk 
assessment in developing treatments to reduce FOH.  
 
• The findings do have several implications for interventions, for example that 
persons with high risk of hypoglycemia and FOH would benefit from risk 
reduction and possibly also strategies to handle anxiety, while persons with low 
risk of hypoglycemia and FOH might benefit from exposure and bio-
psychoeducational interventions aimed at symptom detection and accurate 
treatment of hypoglycemia.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Typ 1 diabetes är en kronisk sjukdom som kräver livslång behandling för överlevnad. 
Personer som är drabbade måste tillföra kroppen insulin flera gånger dagligen och 
anpassa många beteenden för att kunna hantera sjukdomen effektivt. Målet med 
behandlingen är att uppnå god blodockerkontroll för att undvika komplikationer som 
kan uppkomma bl a genom skador på kärl och nerver. Detta mål nås inte av en 
majoritet av alla som har typ 1 diabetes. Orsakerna till detta är individuella, men 
vanliga hinder är att egenvården upplevs vara svår och betungande, samt att olika 
rädslor kan vara kopplade till behandlingen. Program baserade på kognitiv 
beteendeterapi har visat sig vara användbara vid en rad andra kroniska sjukdomar men 
det finns ännu så länge inte tillräckligt med stöd för att det är en effektiv metod för 
vuxna personer med typ 1 diabetes och otillfredsställande blodsockerkontroll. Ett 
vanligt hinder för god sjukdomskontroll är rädsla för hypoglykemi (lågt blodsocker). 
Det behövs instrument av god kvalitet för att kunna bedöma denna rädsla, liksom mer 
kunskap om faktorer som påverkar rädslan för att i förlängningen kunna utveckla 
behandling för att minska rädsla för hypoglykemi och därmed uppnå så god egenvård 
och blodsockerkontroll som möjligt. 
 
Den första studien i denna avhandling utvärderar effekten av en intervention baserad på 
kognitiv beteendeterapi (KBT). Deltagarna blev slumpmässigt utvalda till att antingen 
få KBT-behandling (intervention) eller till att fortsätta med sedvanlig diabetesvård 
(kontrollgrupp). KBT-behandlingen gavs mestadels i grupp, men även individuella 
träffar ingick i interventionen, som bestod av ett grundprogram om 8 veckor, och ett 
vidmakthållandeprogram.  I grundprogrammet fick deltagarna kartlägga sina 
egenvårdsbeteenden och lära sig verktyg för att åstadkomma en beteendeförändring. 
Vidmakthållandeprogrammet syftade till att hjälpa deltagarna att fortsätta med 
beteendeförändringarna och förebygga bakslag. Totalt pågick studien under ett år. Vid 
studiens slut hittades signifikanta skillnader mellan interventionsgruppen och 
kontrollgruppen avseende blodsockerkontroll, välbefinnande, upplevd stress, rädsla för 
hypoglykemi, depression och ångest, där interventionsgruppen förbättrades mer än 
kontrollgruppen. Slutsatsen är att KBT-programmet förefaller vara en lovande 
behandling för att förbättra blodsockerkontrollen och det emotionella välbefinnandet 
hos vuxna personer med typ 1 diabetes och otillfredsställande blodsockerkontroll. 
 
För att kunna identifiera och bedöma rädsla för hypoglykemi hos vuxna med typ 1 
diabetes översattes och utvärderades ett självskattningsinstrument, Hypoglycemia Fear 
Survey (HFS), ursprungligen utvecklat i USA. Utvärderingen granskade genom 
statistiska metoder huruvida instrumentet mäter det som avses att mätas, samt om det 
mäter begreppet på ett tillförlitligt sätt. Resultatet visar att den svenska versionen av 
HFS är tillförlitligt med avseende på dessa aspekter. 
 
Studie III och IV syftade till att utforska faktorer som är kopplade till rädsla för 
hypoglykemi och därmed kan spela roll för uppkomst och vidmakthållande av 
problemet. Syftet med detta är att identifiera faktorer som är viktiga att ta hänsyn till 
vid utvecklandet av en behandling för att minska rädslan. Båda studierna ufördes 
genom att enkäter skickades till patienter med typ 1 diabetes. Studie III undersökte 
sambandet mellan rädsla för hypoglykemi och faktorer kopplade till sjukdomen samt 
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demografiska faktorer. Resultatet visade ett starkt samband mellan att ha haft tidigare 
episoder av svår hypoglykemi och hög rädsla för hypoglykemi, samt att rädslan 
förefaller vara vanligare hos kvinnor än män. Studie IV undersökte förutom sambandet 
med demografiska och sjukdomsspecifika faktorer även samband med emotionella och 
psykosociala faktorer. Resultatet visar att det finns ett starkt samband mellan rädsla för 
hypoglykemi och ångest, rädsla för ångestsymtom samt social ångest. Studien visar 
också att det verkar finnas skillnader i faktorer kopplade till rädslan i olika subgrupper 
av patienter. Dessa skillnader kan vara viktiga att beakta när behandling för rädslan 
utvecklas  
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APPENDIX

Swe-HFS översatt och psykometriskt testat, Anderbro et al, Patient Education and Counseling, 2009 
 
 
 
 
 
 
 
Nedan finner du en lista på åtgärder som personer med diabetes gör i avsikt att 
undvika lågt blodsocker. Läs varje fråga noggrant. Sätt en cirkel runt den siffra 
som bäst beskriver hur Du gör i det dagliga livet för att UNDVIKA lågt 
blodsocker.  
    
Aldrig 
 
Sällan  Ibland 
 
Ofta  
 
 
Alltid 
 1.  Äter ett större mellanmål före sänggåendet 0 1 2 3 4 
 2.  Undviker att vara ensam om blodsockret är 
neråtgående 
0 1 2 3 4 
 3.   Då jag testar blodsockret, ser jag till att ha lite 
högre blodsocker för att vara på den säkra sidan 
0 1 2 3 4 
 4.  Håller mitt blodsocker högre om jag kommer att 
vara ensam ett tag 
0 1 2 3 4 
 5.  Äter något så fort som jag känner symptom på 
lågt blodsocker 
0 1 2 3 4 
 6.  Tar mindre insulin när jag tror att mitt 
blodsocker är lågt 
0 1 2 3 4 
 7.  Håller mitt blodsocker högre om jag skall 
deltaga i ett långt möte eller gå på fest 
0 1 2 3 4 
 8.   Bär druvsocker med mig 0 1 2 3 4 
 9.  Undviker motion när jag tror att mitt blodsocker 
är lågt 
0 1 2 3 4 
10.   Kontrollerar mitt blodsocker ofta om jag skall 
deltaga i ett långt möte eller gå på fest                     
0 1 2 3 4 
 
 
 
Swe-HFS 
Hypoglykemiformulär 
 
Swe-HFS översatt och psykometriskt testat, Anderbro et al, Patient Education and Counseling, 2009 
 
Nedan finner Du en lista på bekymmer som personer med diabetes ibland 
upplever. Läs varje fråga noggrant. Sätt en cirkel runt den siffra som bäst 
beskriver hur ofta Du är OROLIG i varje situation på grund av lågt blodsocker. 
 
Jag oroar mig för…… 
    
Aldrig 
 
Sällan  Ibland 
 
Ofta  
 
 
Alltid 
11.  Att inte uppleva/inse att blodsockret är lågt 0 1 2 3 4 
12.  Att inte ha bröd, frukt eller juice med mig 0 1 2 3 4 
13.   Att svimma av offentligt 0 1 2 3 4 
14.  Att ”göra bort mig” eller mina vänner då vi 
umgås 
0 1 2 3 4 
15.  Få en insulinkänning då jag är ensam  0 1 2 3 4 
16.  Verka som om jag är dum eller berusad  0 1 2 3 4 
17.  Förlora kontrollen 0 1 2 3 4 
18.   Att ingen finns i närheten om jag får en 
insulinkänning 
0 1 2 3 4 
19.  Få en insulinkänning då jag kör bil 0 1 2 3 4 
20.   Att göra ett misstag eller råka ut för en olycka 0 1 2 3 4 
21.  Bli felaktig bedömd eller bli kritiserad 0 1 2 3 4 
22.  Att inte kunna tänka klart då jag är ansvarig för 
andra 
0 1 2 3 4 
23.  Känna mig yr eller snurrig 0 1 2 3 4 
 
Cox DJ et al, 1987 
 
 
